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SUMMARY 
The timely assessment and treatment of dyslipidaemia is an important component of 
cardiovascular risk screening and intervention. The apolipoprotein E (APOE) ε-2/ε-3/ε-4 
polymorphism associated with impaired lipid homeostasis provides a genetic link between 
cardiovascular disease (CVD) and late-onset Alzheimer’s disease (AD). Realization that the 
phenotypic expression of the risk associated APOEε-2 and ε-4 alleles may be dependent on 
non-genetic factors supports the inclusion of APOE genotyping in chronic disease screening 
programs. The lack of well-defined selection criteria for APOE genotyping, however, limits 
the use of this biomarker in clinical practice.  
 
The aim of the present study was to develop a pre-screen algorithm for identification of a 
target population most likely to benefit from APOE genotyping, performed in conjunction with 
a clinical and lifestyle assessment. Towards this goal, comprehensive patient data were 
evaluated from a total of 580 unrelated Caucasians enrolled in a chronic disease screening 
program over a five-year period (2010-2015), using an ethically approved study 
questionnaire. Biochemical tests performed according to standard laboratory protocols were 
extracted from the research database. All study participants were genotyped for the APOE ε-
2/ε-3/ε-4 polymorphism.  
APOE genotype distribution differed significantly (p<0.05) between study participants with 
and without a family history of AD. A positive association between dietary fat intake and low-
density lipoprotein (LDL) cholesterol (p=0.001), as well as an inverse association with high-
density lipoprotein (HDL) cholesterol (p=0.002), were observed in patients with a family 
history of AD. Body mass index (BMI) was positively associated with LDL cholesterol and 
inversely associated with HDL cholesterol levels (p<0.001), irrespectively of an AD family 
history. Smoking was associated with higher triglycerides (p<0.001) and lower HDL 
cholesterol levels (p=0.004) in the total study group. Alcohol intake was positively associated 
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with BMI (p=0.008) as well as triglyceride levels (p=0.021) in patients with a positive family 
history of AD. The clinical expression of a hypercholesterolaemic phenotype in APOE ε-4 
allele carriers, as well as apparent mitigation by regular physical activity, were dependent on 
the interaction between a family history of AD and APOE genotype (p<0.001). APOE ε-2 
carriers without an AD family history showed a significant increase in triglyceride levels 
(p=0.014). The modulating influence of APOE ε-4 on the relationship between alcohol intake 
and BMI as well as total cholesterol levels was also dependent on the presence or absence 
of AD family history (p<0.05).  
 
This study resulted in the addition of a family history of AD as a novel component to the pre-
screen algorithm developed for selection of at-risk individuals prior to APOE genotyping 
performed as part of a chronic disease screening program. The lifestyle questionnaire used 
in this study furthermore facilitated interpretation of the clinical relevance of variation 
detected in the APOE gene. This is important to prioritize the use of lipid-lowering 
medication towards patients with severe subtypes of dyslipidaemia such as familial 
hypercholesterolaemia (FH), which remains largely undiagnosed and untreated in the high-
risk South African population. Incorporating the research findings into clinical practice 
would suggest that physical activity may be the most effective risk reduction strategy in 
carriers of the APOEε-4 allele, as supported by international studies. 
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OPSOMMING 
Die tydige opsporing en behandeling van dislipidemie is 'n belangrike komponent van 
kardiovaskulêre risikobepaling en intervensie. Die apolipoproteïn E (APOE) ε-2/ε-3/ε-4 
polimorfisme wat geassosieer is met abnormale lipied metabolisme toon ‘n genetiese 
verband tussen kardiovaskulêre siekte (KVS) en laat- aanvang Alzheimer se siekte (AD). Die 
bevinding dat die fenotipiese uitdrukking van die risiko geassosieerde APOE ε-2 en ε-4 allele 
afhanklik mag wees van nie-genetiese faktore ondersteun die insluiting van APOE 
genotipering in kroniese siekte siftingsprogramme. Die gebrek aan goed-gedefinieerde 
seleksie kriteria vir APOE genotipering beperk egter die gebruik van hierdie biomerker in 
kliniese praktyk.  
 
Die doel van hierdie studie was om 'n pre-toets algoritme te ontwikkel vir identifikasie van ‘n 
teiken populasie waar APOE genotipering waarde kan byvoeg, tesame met die evaluering 
van kliniese en leefstyl risikofaktore.  Om hierdie doel te bereik is pasiëntdata geanaliseer 
van ‘n totaal van 580 nie-verwante Koukasiërs wat deelneem aan ‘n kroniese siekte 
siftingsprogram oor ‘n vyf-jaar periode (2010-2015), met gebruik van ‘n eties goedgekeurde 
studievraelys. Biochemiese toetse wat uitgevoer is volgens standaard laboratorium 
protokolle is geëekstraheer uit die navorsingsdatabasis. Genotipering van alle 
studiedeelnemers is uitgevoer vir die APOE ε-2/ε-3/ε-4 polimorfisme.  
 
APOE genotipe verspreiding het betekenisvol verskil (p<0.05) tussen studiedeelnemers met 
en sonder ‘n familiegeskiedenis van AS. ‘n Positiewe assosiasie is waargeneem tussen vet-
inname in die dieet en lae-digtheid lipoproteïen (LDL) cholesterol (p=0.001), terwyl ‘n 
omgekeerde assosiasie met hoë-digtheid lipoproteïen (HDL) cholesterol (p=0.002) 
waargeneem is in deelnemers met ‘n familiegeskiedenis van AS. Liggaamsmassa-indeks 
(BMI) was positief geassosieer met LDL cholesterol en omgekeerd geassosieer met HDL 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
cholesterolvlakke (p<0.001), ongeag van AS familiegeskiedenis. Rook was geassosieer met 
verhoogde trigliserides (p<0.001) and laer HDL cholesterolvlakke (p=0.004) in die totale 
studiegroep. Alkohol inname was positief geassosieer met BMI (p=0.008) asook 
trigliseriedvlakke (p=0.021) in deelnemers met ‘n positiewe familiegeskiedenis van AS. Die 
kliniese uitdrukking van ‘n hipercholesterolemiese fenotipe in APOE ε-4 alleel draers, asook 
die verlaagde cholesterolvlakke met gereëlde fisiese aktiwiteit, was afhankik van die 
interaksie tussen AS familiegeskiedenis en APOE genotipe (p<0.001). APOE ε-2 draers 
sonder ‘n AS familiegeskiedenis het ‘n betekenisvolle verhoging in trigliseriedvlakke getoon 
(p=0.014). Die modulerende invloed van APOE ε-4 op die verhouding tussen alkohol inname 
en BMI asook totale cholesterolvlakke is ook bepaal deur die teenwoordigheid al dan nie van 
‘n AS familiegeskiedenis (p<0.05).  
 
Hierdie studie het gelei tot die byvoeging van ‘n familiegeskiedenis van AS as ‘n nuwe 
komponent tot die pre-toets algoritme wat ontwikkel is om hoë-risiko individue te selekteer 
voor APOE genotipering as deel van n kroniese risiko bestuur program. Die leefstyl vraelys 
wat gebruik is vergemaklik die interpretasie van die kliniese relevansie van die genotipe 
resultate. Dit is belangrik sodat die noodsaaklikheid van lipied-verlagende farmakoterapie 
geprioritiseer kan word in deelnemers met erge subtipes van dislipidemie soos familiële 
hipercholesterolaemie (FH), wat meestal ongediagnoseer en onder-behandel bly in die hoë-
risiko Suid-Afrikaanse populasie. Inkorporering van die navorsingsresultate in kliniese 
praktyk behels die aanbeveling van fisiese aktiwiteit as die mees effektiewe risikoverlagende 
strategie in draers van die APOE ε-4 alleel, soos ook ondersteun word deur intenasionale 
studies. 
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LIST OF ABBREVIATIONS 
A 
A-β: amyloid beta  
AChEI: acetylcholine esterase inhibitors  
AD: Alzheimer’s disease 
ANCOVA: analysis of covariance  
APOE: apolipoprotein E 
 
B 
BMI: body mass index  
BNP: brain natriuretic peptide 
 
C 
CAA: cerebral amyloid angiopathy  
CRP: C-reactive protein 
CVD: cardiovascular disease  
CYP2D6: cytochrome P450 
 
D 
DIOS: dysmetabolic iron overload syndrome 
DTC: direct to consumer  
 
F 
FH: familial hypercholesterolemia  
 
G 
GWAS: genome-wide association studies  
 
H 
HCP: healthcare professional  
HDL: high-density lipoprotein 
HER2: human epidermal growth factor 2 
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HFE: hemochromatosis  
HREC: health and research ethics committee  
 
I 
IL-6: interleukin-6 
IQR: interquartile range  
 
L 
LDL: low-density lipoprotein  
LDLR: low-density lipoprotein receptor  
LOAD: late-onset Alzheimer’s disease 
 
M 
MDR: multifactor-dimensionality regression 
 
N 
NCD: non-communicable disease  
NFT: neurofibrillary tangle 
 
P 
PSGT: pathology-supported genetic testing  
 
R 
RCT: randomized controlled trial 
RXR: retinoid x receptor  
 
S 
SD: standard deviation  
 
W 
WHO: world health organization 
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INTRODUCTION 
The coordinated interaction between the low-density lipoprotein receptor (LDLR) underlying 
familial hypercholesterolaemia (FH) and apolipoprotein E (APOE) as the primary ligand of 
the LDLR forms the basis for the metabolic regulation of cholesterol. Determination of 
cholesterol levels forms an integral part of population-based chronic disease / wellness 
screening programs aimed at prevention of cardiovascular disease (CVD) and other non-
communicable diseases (NCDs). This is of particular relevance in South Africa, where the 
prevalence of FH is increased 5-10 times compared to most other populations in the world 
due to a founder effect. This led to the development of a cost-effective test for FH based on 
a limited number of founder mutations responsible for the disease in the majority of affected 
patients in South Africa. The finding that polymorphic variation in the APOE gene contributes 
more to fluctuation in lipid levels in the general population (Siest et al. 1995) than any other 
gene identified to date, highlights the potential role of genetic testing for identification of 
dyslipidaemia subtypes with different treatment requirements.  
The APOE ε-2/ε-3/ε-4 polymorphism is one of the most extensively studied genetic 
variations underlying CVD in the general population. The cholesterol-raising APOE ε-4 allele 
was furthermore identified as the most important genetic risk factor for late-onset 
Alzheimer’s disease (AD), which shows striking pathogenic overlap with CVD. In this 
context, a growing body of evidence supports the role of the APOE ε-2/ε-3/ε-4 polymorphism 
as an important target for risk reduction intervention in chronic disease screening programs. 
The lack of well-defined eligibility criteria for identification of a subgroup of the population set 
to derive optimal benefit from APOE genotyping limits the use of this biomarker in clinical 
practice. In addition, clinicians remain hesitant to refer patients for APOE genotyping due to 
the association between the ε-4 allele and increased risk for AD, considered an incurable 
disease.  APOE genotype also has limited individual utility as a diagnostic, predictive and 
prognostic marker in the assessment of cardiovascular risk. This could be explained by the 
fact that genetic risk conferred by the APOE ε-2/ε-3/ε-4 polymorphism is context-dependent, 
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with its deleterious effects expressed only in a high-risk environment. This knowledge also 
provides an opportunity for risk reduction at the gene-environment level. 
Family history is routinely used to determine eligibility for high-penetrance mutation 
screening used to confirm a suspected diagnosis of Mendelian disorders such as FH. 
However, the clinical usefulness of a family history for selection of high-risk individuals most 
likely to benefit from a chronic disease screening program including APOE genotyping, 
remains unclear. In this context, we investigated whether a family history of AD could serve 
as the basis for a pre-screen algorithm that can be applied prior to APOE genotyping in 
order to facilitate the development of tailored treatment paths in a subgroup of dyslipidaemic 
patients at increased risk of CVD and/or AD. Towards this goal, a retrospective evaluation of 
prospectively collected data of nearly 600 study participants was performed with specific 
emphasis on the clinically actionable APOE polymorphism. Data was extracted from a 
secure centrally maintained research database was assessed with the use of a preliminary 
statistical tool to determine the value of APOE genotyping as a component of chronic 
disease screening in the South African population. Clinical information in this database was 
corroborated with data contained in patient files, including verification of appropriate patient 
consent.  
The thesis is presented in four chapters, starting with a review of the literature (Chapter 1), 
relevant to the purpose of the study. Data from two sub-studies written as original articles 
published in scientific journals are subsequently presented. In the first sub-study (Chapter 2) 
we present data which supports the clinical relevance of inquiry concerning AD family history 
as part of a pre-screen selection step for APOE genotyping. In the second sub-study 
(Chapter 3) the value of a questionnaire-based lifestyle assessment is evaluated to allow for 
appropriate clinical interpretation of APOE genotyping results. Conclusions from this 
research project are presented in Chapter 4, followed by the Appendix including supporting 
material.  
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CHAPTER 1 
LITERATURE REVIEW 
 
 
1.1. INTRODUCTION 
Genomic medicine is based on the assumption that risk for the onset and pathogenic 
progression of most clinical disorders is modified or determined by genetic factors. Recent 
technological developments have advanced our understanding of the genetic basis 
underlying the pathogenesis of chronic multifactorial non-communicable diseases (NCDs) 
considered a primary contributor to global morbidity and mortality (Murray and Lopez 2013). 
Increasing appreciation for this shared genetic architecture underpinning the etiopathogenic 
basis of most chronic multifactorial disorders, provides a strong incentive for the 
development of a unifying health model allowing for the evaluation of current and future 
disease risk to promote wellness throughout the course of a person’s lifespan (Kotze et al. 
2013; Li et al. 2013). 
 
The successful integration of genetic testing as a routine component of patient care has the 
capacity to advance a paradigm shift away from “reactive medicine” in favour of a new 
healthcare model which resonates with the principles and ideals of personalized medicine 
(Hood 2013). A number of limitations however impede the adoption of genomics in general 
medical practice and continue to widen the gap between the generation of increasingly 
complex genetic data and the reality of its application to improve long-term health outcomes 
(Khoury et al. 2007). It is imperative that these factors be addressed in order to enable the 
integration of genomics as a routine component of patient care. 
 
In this literature overview, we discuss existing limitations which impede the advancement of 
a genomics-based approach to chronic disease screening, in addition to those inherent to a 
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genetics-only approach to risk management and intervention. A pathology-supported genetic 
testing (PSGT) model (Kotze et al. 2015) is presented as a means of incorporating screening 
into existing risk classification models as part of a multidisciplinary approach to patient 
management. In conclusion, the value of using a pathways-based approach to validate the 
appropriateness of genetic testing related to dyslipidaemia is considered with specific 
emphasis on a functional polymorphism (ε-2/ε-3/ε-4) in the APOE gene.  
 
1.2. Limitations impeding the widespread clinical adoption of genetic testing 
The general public is becoming increasingly aware of the potential harms associated with 
inappropriate genetic testing, including loss of privacy, breach of confidentiality, 
stigmatization and employment as well as insurability concerns. To ensure its appropriate 
use, a code of conduct has been compiled for the insurance industry in South Africa 
(reviewed by Kotze et al. 2004). The code aims to promote the fair, equitable, confidential 
and evidence-based handling of genetic information.  
 
The most efficient and practical means to integrate, interpret and communicate genetic data 
to inform clinical decision making remain imprecisely defined (Guttmacher et al. 2007). A 
lack of sufficient pre- and post-clinical training and experience in genomics contributes 
towards a lack of expertise and confidence among healthcare practitioners (HCPs) in 
handling certain genetic services by themselves within the framework of existing 
management strategies to improve patient outcomes. Clinician education should ideally 
include basic knowledge of a variety of areas of clinical relevance including the principles 
and indications for genetic testing, the role of genetic counsellors, the clinical value of 
currently available tests as well as interpretation of genetic information. Haspel et al. (2010) 
suggested that the existing curriculum for pathology training in North America should include 
a greater emphasis on genomics education and personalized medicine. Similarly, the 
National Human Genome Research Institute appealed for improved strategies to enhance 
the confidence of HCPs to refer for genetic testing (Feero and Green 2011). 
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In order to affirm the demand for greater education and training in genomics, existing 
perceptions and knowledge of HCPs regarding the utility of genetic testing, particularly in the 
development of tailored therapeutic algorithms to optimize patient care, needs to be 
established.  Eisinger et al. (2008) used a questionnaire-based survey to assess the 
opinions of 600 general practitioners and 1504 members of the public regarding screening 
tests for cancer. The authors found surprising disagreement between evidence-based 
recommendations for genetic testing and actual clinical practices. Clinicians tended to 
overestimate the negative psycho-dynamic impact of testing results on patients, whilst failing 
to appreciate the importance of their role in testing initiation and result interpretation. 
Klitzman et al. (2013) recently confirmed the need for further HCP training regarding the 
indications for genetic testing, patient counselling, interpretation of genetic information and 
maintenance of confidentiality and privacy. This study further found that patient inquiry 
regarding genetic testing was more strongly associated with the requesting of such tests 
rather than being prompted by patient-care objectives. These findings were echoed in an 
earlier study by Sifri et al. (2003) in which the authors found that the application of genetic 
screening tests for cancer were primarily affected by patient inquiry, and lastly by the 
practice environment of the provider. In summary, a solely education-based focus 
concerning the principles underlying genetics is insufficient in accomplishing these goals. 
Unless current attitudes towards genetic testing are also addressed, and the reasons behind 
clinical hesitancy towards its integration defined, genomics will remain an underutilized 
resource in healthcare, despite substantial government and private investments into 
research and training of medical scientists. 
 
1.3. Limitations imposed by a genomics-only approach to NCD risk screening 
An ongoing shift in research focus from the limited scope of high-penetrance Mendelian 
disorders to polygenic NCDs requires that the analytical validity and clinical utility of common 
single-nucleotide polymorphisms (SNPs) be established. This issue is further complicated by 
the lack of a clear distinction between genetic variants considered as “causative mutations”, 
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“genetic risk modifiers” and “susceptibility variants” (Donahue et al. 2006; Kotze et al. 2013). 
It is therefore imperative to determine whether personalized genomic testing performed as 
part of comprehensive NCD risk assessment is able to accurately predict adverse clinical or 
therapeutic outcomes at the individual level. Establishing whether a given genomic test with 
sufficient predictive accuracy as supported by clinical evidence brings about a change in 
patient management is considered an important further milestone towards the confirmation 
of clinical utility as a prerequisite for the routine clinical implementation of emerging genomic 
applications (Janssens and van Duijn 2008).  
 
Genome-wide association studies (GWAS) have identified thousands of common 
susceptibility variants as putative genetic risk modifiers across a broad spectrum of chronic 
NCDs (Cluett and Melzer 2009). These risk-associated variants however fail to reach 
significance in population-based studies and have limited utility as individual risk predictors 
in complex phenotypic traits (Janssens and van Duijn 2008; Pharoah et al. 2008). It has 
been proposed that genotype risk scores incorporating a sufficient number of susceptibility 
variants functioning in known pathogenic pathways could reach statistical significance to the 
extent that a substantial proportion of phenotypic variance for a particular trait is explained 
(Janssens et al. 2006). For a polygenic risk prediction model to be developed and validated 
in such a way that it accurately identifies people at increased NCD risk, the research study 
needs to be performed using a sufficient and often very large sample size for the number of 
susceptibility variants considered, which is not always practical or logistically feasible in 
resource-limited environments (Janssens et al. 2006; Chatterjee et al. 2013).  
 
The majority of genotype risk scores developed to date have failed to reach sufficient 
discriminatory power required to accurately predict individual risk for etiologically complex 
NCDs such as type II diabetes mellitus (Meigs et al. 2008; Liu and Song 2010). The 
predictive value of such polygenic risk models is further limited by the prevalence and 
degree of heritability for the NCD of interest: as such, a genotype-only approach to NCD risk 
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prediction could equate but likely not supersede existing clinical assessment schemes, with 
the exception of perhaps a limited number of restricted applications (Janssens and van Duijn 
2008). It does however appear that the addition of a simple genomics component comprising 
a limited number of susceptibility variants to existing clinical risk prediction algorithms 
significantly  improves their performance in predicting individual risk for the development or 
progression of NCDs including coronary artery disease (Humphries et al. 2007) and 
malignant melanoma (Cust et al. 2014). This may be compared to the use of limited mono-
variant testing such as hemochromatosis (HFE) genotyping used as a viable alternative to 
invasive liver biopsy in diagnosing patients with type I hereditary hemochromatosis (HH), as 
previously reviewed by Kotze et al. (2009) in relation to other causes of iron dysregulation. 
While a number of metabolic causes for hepatic iron overload exist, there is increasing 
interest in the dysmetabolic iron overload syndrome (DIOS) as the most common differential 
diagnosis for type I genetic HH in obese patients. Increased serum ferritin as the only reason 
to refer patients to HFE genotyping may lead to the erroneous diagnostic confirmation of 
genetic HH in patients for whom DIOS is rather more likely based on a compatible clinico-
biochemical profile despite incidental HFE mutation carriage (Riva et al. 2008). 
 
A notable advantage of polygenic risk models over single-variant analysis is their ability to 
reflect the additive effects of multiple susceptibility variants on NCD risk or clinical outcomes. 
These genotype risk scores are often based solely on allelic summation and mostly fail to 
consider the importance of synergistic interactions between the risk variants of interest as a 
major determinant of functional outcomes (Onay et al. 2006; Machiela et al. 2011). This 
shortcoming is intrinsically related to the limited capabilities of parametric statistical methods 
to characterize the impact of risk genotypes on phenotypic expression patterns when they 
are to an extent dependent on epistatic interactions with other susceptibility variants 
(Templeton 2000). Not only are case-control studies not ideal for evaluating the long-term 
impact of genetic testing on clinical decision-making and patient outcomes, but different 
statistical methods vary in their ability to model the influence of risk-associated genetic 
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variants on NCD risk. For example, while logistic regression is a statistical classification 
method often used to determine how accurately a set of putative risk genotypes can predict 
a binary clinical outcome, this approach is considered impractical for modelling higher-order 
variant-variant interactions: owing to the high frequency of empty contingency-based cells, 
data sparseness can lead to 1) the standard error of the regression coefficient being very 
large, increasing the probability of a type II error occurring, or 2) failure of model 
convergence, resulting in the regression coefficients derived there from being of limited 
value (Hosmer and Lemeshow 2000). Model-free statistical methods including multifactor-
dimensionality reduction (MDR) have been proposed as a more useful alternative for 
effectively modelling higher-order epistatic effects, although this technique is itself limited 
insofar as it is computationally intensive given the incorporation of a large number of risk 
variants (Ritchie et al. 2001).  
 
It can therefore be argued that it is simply no longer appropriate to consider a genotype-only 
approach to NCD risk management as the ideal conceptualization of how low-penetrance 
genomic testing should be applied to predict the onset or clinical progression of multifactorial 
polygenic conditions or adverse long-term clinical and therapeutic outcomes. It is imperative 
that the correct study design be used as well as the correct statistical tools to factor in the 
importance of environmental and epistatic factors as modifiers of phenotypic expression 
associated with carriage of a particular risk variant. The limited utility of isolated genetic 
testing as the sole basis for clinical risk prediction in chronic NCDs is further complicated by 
the significant variability in particular platforms and predictive algorithms used, as well as 
functional polymorphisms selected for inclusion in specific multi-gene testing assays. This 
has yielded significant diversity in risk estimation even for the same individual (Imai et al. 
2011; Kalf et al. 2014). As most multifactorial conditions are considered complex phenotypic 
traits, isolated allelic variations are largely insufficient in accounting for clinical emergence, 
which is rather dependent on multiple environmental and epistatic drivers of phenotypic 
expression acting upon a polygenic susceptibility background. Summarily, considering 
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genetic testing results in isolation most likely profoundly limits the capacity for accurate risk 
assessment and stratification (Donahue et al. 2006; Kotze et al. 2013). 
 
1.4. Population-based genetic susceptibility screening for common adult-onset NCDs 
In South Africa, population-based screening for genetic diseases has historically been 
restricted to screening asymptomatic high-risk individuals for monogenic disorders with 
increased prevalence in certain local population groups due to a so-called “founder effect” 
(Kotze et al. 2015). Recent advances in genomic understanding have sparked a renewed 
interest in population-based screening for genetic susceptibility towards common adult-onset 
NCDs. Genetic susceptibility screening in a specific target population or subgroup will enable 
clinicians to facilitate the timely implementation of tailored lifestyle-based intervention 
strategies (“primary prevention”) as well as provide targeted pharmacotherapy to those 
already affected (“secondary prevention”).  
 
These ideals echo the PSGT pathways-based approach to the genetic characterization of 
distinct NCD subtypes aimed at informing clinical decision making and guiding the selection 
of appropriate treatment (Kotze et al. 2015). In this context, “pathways” is referred to the in 
the context of dysfunctional regulation of cholesterol/folate/iron metabolism as well as 
thrombophilia implicated in CVD and related comorbidities associated with the metabolic 
syndrome. Wilson and Jungner (1968) initially proposed a set of screening criteria (Table 1) 
adopted by the World Health Organization (WHO) and long considered the gold standard for 
determining whether population-based screening is applicable to a particular medical 
condition. Effective evidence-based genetic screening has significant potential for advancing 
the clinical translation of emerging genomic insights into practical healthcare benefits at the 
population level. There is however a general consensus among public health experts that a 
number of important limiting factors inherent to genetics-based screening first need to be 
addressed before population-based testing can be recommended as routine, as previously 
discussed. 
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Table 1.World Health Organization (WHO) population-based screening criteria [Wilson and 
Jungner 1968]. 
1 Medical condition is identified as an important health concern  
2 Treatment for medical condition in question is available  
3 Facilities for disease diagnosis and treatment should be available and functional  
4 The clinical course of the medical condition including its latent phase should be understood 
5 A suitable test or examination should be available  
6 Test or examination in question should be relevant  to the target population   
7 Natural history of disease should be adequately understood  
8 Policy concerning eligibility/indications for treatment should be in place 
9 Total cost attributed to finding a case economically balanced in relation to total medical 
expenditure (cost-effective) 
10 Case finding should be viewed as an ongoing continuous process  
 
 
1.5. Clinical research translation: from novel genomic test to practical healthcare 
implications  
The successful introduction of a novel genomic test as a routine component of patient care 
necessitates a framework which supports a “continuum” of clinical translation from original 
genotype-phenotype data to powerful new genomic tools capable of improving long-term 
health outcomes. The PSGT model enabled by an open-innovation platform linking routine 
genetic testing to the generation of a secure centrally maintained online genomics database 
resource provides just such a framework (Kotze et al. 2015). 
 
The “ideal” approach to genomics-based chronic disease risk assessment should be 
accompanied by adherence to a core set of principles which govern population-based 
screening approaches to common adult-onset conditions. These principles were first outlined 
by Wilson and Jungner in 1968 for the World Health Organization (Table 1) and later 
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modified by several authors and regulatory bodies (Table 2) as reviewed by Andermann et 
al. (2008). In this context, it is becoming accepted that a logistically feasible, cost-effective 
genetic screening program should respond to a particular healthcare concern identified for 
the target population of interest. In addition, the genetic test and corresponding intervention 
should be provided according to clearly defined objectives and supported by a substantial 
body of high-quality evidence regardless of outcome. These cardinal principles (Table 2) 
could provide a useful framework for the development of public healthcare policies to ensure 
that the necessary legislative frameworks and regulatory bodies are put in place to oversee 
ethical and transparent research conduct. This could minimize the potential for public 
apprehension and anxiety concerning loss of privacy and confidentiality, data sharing and 
genetic discrimination (Khoury et al. 2007). 
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Table 2. Adapted set of core principles governing population-specific genetic susceptibility 
testing for common adult-onset NCDs (adopted from review by Andermann et al. 2008). 
Category  Core principle 
Positioning of genomic test 
in relation to population-
based healthcare concern 
 
Genomic test positioned as response to an important 
healthcare issue which imposes significant morbidity and 
mortality in the target population of interest 
 
Frequency and phenotypic associations of risk variant known 
for target population  
 
Efficacy of corresponding intervention in target population 
supported by high-quality clinical evidence   
 
Quality assurance and 
logistic feasibility of genomic 
test 
Analytical validation of novel genomic test against existing 
laboratory standards  
 
Centrally maintenance of secure data storage resource  
 
Cost-effectiveness of genomic test in relation to corresponding 
intervention in target population   
 
Ethico-legal dilemmas and 
cost issues  
Potential for psychological harm / risk-benefit ratio 
 
Impact on insurability of information used for actuarial 
underwriting  
 
Willingness to pay in relation to test reimbursement  
 
 
1.6. Pathology-supported genetic testing as a novel approach to personalized 
genomics 
An effective genomics-based approach to chronic disease risk screening should reflect the 
limited capacity for clinical application imposed by single-gene assessment inherent to 
direct-to-consumer (DTC) testing in complex multifactorial disorders, which limits the 
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capacity for clinical translation of genomic research (Donahue et al. 2006; Imai et al. 2011; 
Kotze et al. 2013; Kalf et al. 2014). The consideration of genetic testing results in relation to 
phenotypically enriched patient data could however allow for comprehensive chronic disease 
risk assessment aimed at promoting the optimal use of personalized genomics to guide 
patient management (Kotze et al. 2013; Grant et al. 2013). The integration of molecular 
genomics into multidisciplinary clinical framework has proven both complex and challenging. 
Its correct application however has tremendous potential for advancing disease prevention 
and providing individualized treatment modalities targeting existing metabolic abnormalities 
and shared pathogenic pathways rather than merely the symptomatic manifestations of 
disease.  
 
The value of genetic testing in South Africa was highlighted in a series of local articles 
published between 2005-2006 in the “South African Family Practice” to communicate the 
benefits and limitations of a range of genetic tests available to HCPs at that time. This was 
based on extensive studies performed in the local population over more than a decade. 
These studies focused on illustrating the benefits of genetic testing in well-defined clinical 
domains, including the prevention of adverse and potentially lethal drug reactions in patients 
with breast cancer (Kotze et al. 2005a). This involved the integration of genetic knowledge 
with existing clinical and lifestyle management strategies also for cardiovascular disease 
(CVD) and thrombophilia, associated with an increased risk of Alzheimer’s disease (Kotze 
and Badenhorst 2005d; Kotze et al. 2006) and unexplained recurrent pregnancy loss (Kotze 
et al. 2005a) respectively. These and subsequent studies provided a strong scientific basis 
for the development and implementation of a clinically integrative NCD risk management 
strategy in Southern Africa. The aim is to advance the clinical translation of genomic 
research as part of a combined open-innovation research and service delivery platform. It is 
against this background, based on extensive genetic research conducted in the South 
African setting over more than 20 years, that a novel approach to the clinical integration of 
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personalized genomics, termed pathology-supported genetic testing (PSGT) was developed 
(Kotze et al. 2015).  
 
The PSGT model aims to overcome the limitations inherent to direct-to-consumer (DTC) 
genetic testing by advocating that testing results be considered within a multidisciplinary 
clinician-mediated framework assisted by comprehensive patient data gleamed from diverse 
fields of healthcare linked via the golden thread of pathology. Following informed consent 
from the patient, a questionnaire is used to capture data on personal and family medical 
conditions, medication use and side effects, lifestyle factors and pathology test results 
relevant to the genetic analysis performed (Kotze et al. 2013). Relevant pathological and 
biochemical investigation guided by pre-screening clinical assessment may provide valuable 
insight into existing metabolic abnormalities and underlying disease processes, applicable to 
single-gene testing as well as multi-locus analysis. Using the aforementioned PSGT 
approach, comprehensive patient data is utilized to provide an individualized report to the 
referring clinician, containing clinically actionable information used to guide clinical and 
therapeutic management. A suitable structure for the interpretation of genetic information is 
therefore provided for the purpose of stratifying patients into meaningful prognostic 
subgroups based on the identification of high-risk treatable NCD subtypes requiring a 
tailored approach to therapeutic intervention. 
 
PSGT acknowledges the limitations inherent to single-variant testing to account for the 
phenotypic expression of a disease-associated gene. A multidisciplinary approach is used to 
facilitate the characterisation of treatable NCD subtypes based on the assessment of inter-
related metabolic pathways and associated dysfunctions implicated in a wide range of NCDs 
(Figure 1). This model described by Kotze et al. (2015) allows for the development and 
timely implementation of tailored lifestyle-based intervention strategies which target 
underlying core biological dysfunctions to decrease cumulative disease risk and prevent 
disease progression in affected patients, in addition to affording an opportunity for pre-
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clinical therapeutic mediation to prevent initial development in unaffected individuals. The 
PSGT approach further assists clinicians in the development of tailored pharmacogenomics 
algorithms aimed at predicting treatment failure and limiting exposure to hazardous and 
potentially lethal drug side-effects with the ultimate goal of improving patient compliance.  
 
 
 
Figure 1. Description of a pathology-supported genetic testing (PSGT) strategy used to 
characterize treatable chronic disease subtypes and assess current as well as future risk 
with the goal of informing clinical and therapeutic decision making. 
 
1.7. Use of patient databases as a resource for clinical research translation 
The clinically integrative PSGT model makes use of a combined open-innovation platform 
linking service delivery to the generation of a secure centrally maintained research database 
(accessible to registered users at www.gknowmix.org). PSGT research databases for breast 
cancer and other chronic diseases linked via the common thread of pathology were 
developed to facilitate research translation at the interface between the laboratory bench and 
the bedside.   A number of recent reviews and original articles have discussed the value of 
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this resource for local validation studies aimed at developing pre-screen algorithms for a 
range of genomic applications as well as accompanying treatment pathways. In the context 
of breast cancer leading the way in the application or personalised genomic medicine, the 
following examples of implementation contributed to the development of the genomics 
database resource: 
 
1) Referral guidelines for cytochrome P450 (CYP2D6) genotyping in breast cancer 
patients with comorbid depression treated with a combination of tamoxifen and 
antidepressants (van der Merwe et al. 2012) 
 
2) A pre-screen algorithm and corresponding reimbursement policy for gene expression 
profiling using the 70-gene microarray-based MammaPrint assay, shown to decrease 
the need for adjuvant chemotherapy in South African patients with early-stage breast 
cancer (Grant et al. 2013) 
 
3) Use of microarray-based determination of human epidermal growth factor 2 (HER2) 
tumour status in patients with early-stage breast cancer led to extension of the 
MammaPrint pre-screen algorithm to also include equivocal and borderline-positive 
HER2-positive breast cancer patients (Grant et al. 2015). 
 
1.8. Developing referral guidelines for genomic risk screening 
The development of standardised referral guidelines for inclusion in genomics-based chronic 
disease screening programs is an important step towards the application of genetic testing in 
a goal-directed and cost-effective manner. In this context, eligibility criteria for multi-gene risk 
assessment could ensure that the benefits derived from extended genetic testing outweigh 
the potential for associated harm. Selection criteria for high-penetrance mutation screening 
used increase diagnostic reliability for certain Mendelian disorders and high-risk NCD 
subtypes are already in place based on existing diagnostic guidelines (Kotze et al. 1993; 
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Kotze et al. 2005a-d; Schoeman et al. 2013). In the context of impaired cholesterol 
homeostasis, diagnostic algorithms for FH as a severe monogenic subtype of dyslipidaemia 
found at an increased prevalence in certain South African population groups have been 
developed. This is based on family history, age of disease onset, hypercholesterolaemia 
from birth, and clinical features such as xanthomas characteristic of FH. Due to the clinical 
variability of FH, DNA testing is the method of choice for accurate diagnosis and family 
screening to identify high-risk individuals requiring long-term statin treatment (Kotze et al. 
1994). 
 
There is an ongoing need to develop and validate standardized referral guidelines for 
inclusion of eligible patients in NCD screening programs incorporating a genomics 
component, based on high-quality clinical evidence. The implementation of a pre-screen 
algorithm could serve to identify patients most likely to benefit from genetic testing, in 
addition to preventing unnecessary testing in cases where it is not indicated (Kotze et al. 
2015). Referral guidelines for genomics-based NCD screening would conceivably be more 
complex than existing eligibility criteria for monogenic disorders, and may take the form of a 
multi-step diagnostic algorithm. Clinical factors such as a positive family history of illness and 
early symptom onset/clinical presentation, which play a well-established role in determining 
eligibility for high-penetrance mutation screening, could also prove useful in the development 
of referral guidelines for NCD screening incorporating both mono-variant analysis and multi-
gene risk assays. This notion is supported by a growing body of evidence indicating that 1) 
early-onset subtypes of complex multifactorial NCDs such as major depressive disorder 
(MDD) have a strong genetic basis (Delport et al. 2014), and that 2) the majority of familial 
aggregation for conditions such as breast cancer can also be largely explained by common 
low- to moderate-penetrance susceptibility variants (Gracia-Aznarez et al. 2013). These and 
other observations provide the scientific rationale for ongoing research aimed at determining 
the clinical importance of clinical inquiry concerning family history beyond a purely diagnostic 
scope. 
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While randomized controlled clinical trials (RCTs) are considered the gold standard for 
developing new therapeutic interventions, it remains unclear whether RCTs are always 
indicated for confirming the clinical utility of novel genomic applications as well. RCTs 
require very large sample sizes to conduct, are costly and time-consuming to perform, and 
may therefore not be considered logistically feasible in resource-limited settings. In many 
cases, results from these trials may only become available once the genomic test in question 
is already considered obsolete. A number of alternatives have been proposed, although 
there is currently no consensus on what constitutes the ideal means of overcoming the 
limitations inherent to RCTs. The retrospective evaluation of randomized and prospectively 
collected patient data (“surrogate trials”), which could allow for the conditional approval of 
novel genomic applications under the condition that established eligibility criteria for testing 
formulated from sufficient high-quality evidence supporting the performance and utility of an 
ever-increasing number of genomic tests should already be in place. In this context, an 
open-innovation research and service delivery platform as described in Figure 2 may be 
considered ideally positioned. It allows the development of a preliminary framework aimed at 
promoting the successful clinical implementation of personalized genomic testing performed 
in a defined target population as part of novel multidisciplinary approach to NCD risk 
screening. Ongoing development and improvement of the PSGT research database could 
furthermore facilitate the development and validation of much-needed standardized referral 
guidelines for selection of patients most likely to benefit from genomics-based chronic 
disease screening programs as facilitated by the application of a pathways-based approach 
to the genetic characterization of complex multifactorial NCDs.  
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1.9. A pathways-based approach to genomics-based cardio-metabolic risk screening 
The clinical implementation of a simple and cost-effective screening strategy used to assess 
cardio-metabolic risk could assist in predicting the onset of overt cardiovascular disease 
during the clinically quiescent pre-symptomatic stage (Gilstrap and Wang 2012). Existing 
clinical risk stratification schemes however underestimate risk for cardiovascular disease 
and adverse ischemic events in patients with the metabolic syndrome and/or coexisting 
hepatosteatosis (Dekker et al. 2005; Wannamethee et al. 2005; Khanna et al. 2013). 
Concerns have also been raised over the accuracy of clinical risk stratification schemes such 
as the Framingham risk score in predicting long-term adverse cardiac outcomes, as well as 
their applicability in younger patients. Increasing recognition of these important limitations 
has created interest in the incorporation of emerging biochemical and functional genomic 
markers with the goal of improving the performance of existing risk classification models. 
Since existing cardiovascular risk stratification methods are population-based and therefore 
not necessarily applicable or reach significance at the individual level (Lloyd-Jones 2010), 
further adaptation could prove useful in optimizing cardiovascular risk assessment in certain 
patient subgroups including those with the metabolic syndrome.  
 
The importance of identifying biochemical and functional genomic markers which could add 
value to cardio-metabolic risk assessment and screening lies in the fact that 1) the majority 
of patients with established cardiovascular disease have a limited number of clinical risk 
factors and, 2) vascular disease and its associated comorbidities are characterized by a 
quiescent subclinical stage prior to the symptomatic stage. The routine implementation of a 
novel cardiovascular biomarker would depend on whether it is 1) accurate and reproducible, 
2) easily interpretable, 3) highly sensitive or specific based on the desired outcome, 4) 
explains a reasonable proportion of variation for a particular trait, and 5) to what extent high-
quality clinical evidence supports these assumptions. Hlatky et al. (2009) also emphasised 
that an ideal cardiovascular biomarker should show an incremental increase in predictive 
value over conventional clinical risk markers, with its assessment altering pre-test risk to 
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bring about a change in patient management. In this context, a specific tailored therapeutic 
intervention should also change the individual-specific levels of the biomarker in question, 
which should be equated to a reduction in absolute risk for a particular condition of interest. 
In addition, the incorporation of a novel biomarker as a routine component of patient care is 
predicated on its ability to predict cardio-metabolic risk independently and more accurately 
than conventional risk classification schemes. 
 
There is significant and ongoing interest in the identification and validation of emerging 
biochemical risk markers for cardiovascular disease and its associated ischemic 
complications. In a comprehensive review of 214 meta-analyses, van Holten et al. (2013) 
concluded that the optimal biomarkers for new-onset CVD include those implicated in 
impaired lipid homeostasis and chronic inflammation, with C-reactive protein (CRP) identified 
as the most promising candidate risk marker. In contrast to these findings, several studies 
have failed to show that the addition of CRP to existing clinical risk stratification schemes, 
such as the Framingham risk score, significantly improves their discriminatory power and 
predictive capabilities in the context of cardiovascular risk assessment (Folsom et al. 2006; 
Shah et al. 2009). Therefore, despite the potential for certain biomarkers to predict future risk 
for adverse cardiac events, added value beyond conventional clinical risk markers is 
minimal, with this approach failing to benefit risk reclassification in the majority of patients 
(Melander et al. 2009). Elevated levels of CRP and interleukin-6 (IL-6) reflect a core 
pathogenic process (i.e. chronic inflammation) implicated in the pathogenesis of vascular 
disease and its associated comorbidities. In contrast, other circulating biomarkers such as B-
type natriuretic peptide (BNP) reflect a consequence of cardiac injury, and have been shown 
to outperform CRP in the prediction of future ischemic events and cardiovascular mortality. 
 
A multi-marker approach has been proposed as a means of overcoming the limitations 
inherent to the assessment of individual biochemical markers of cardio-metabolic risk (Wang 
et al. 2006; de Ruijter et al. 2009). Several studies have shown that the assessment of 
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multiple cardiovascular risk markers improves clinical risk prediction and facilitates accurate 
risk reclassification (Zethelius et al. 2008; Blankenberg et al. 2010). These studies have 
however been criticised due to the inclusion of patients with existing cardiovascular disease 
as well as the restriction of the study population to a specific sex and age group. In contrast, 
conflicting studies have shown that, despite the significant association between certain 
biomarkers such as brain natriuretic peptide (BNP) and the urinary albumin-to-creatinine 
ratio, these markers fail to improve the diagnostic capabilities of existing clinical risk 
stratification (Wang et al. 2006; Melander et al. 2009). It seems intuitive that the assessment 
of an increasing number of biomarkers would add additional value to clinical risk 
classification. A limited number of biomarkers (<10) may, however, be sufficient in cases 
where there is little or no correlation between these variables. This notion needs to be 
validated in the routine clinical arena prior to its justification as a sufficient and validated 
approach to cardio-metabolic risk assessment (Wang 2011). 
 
In comparison to biochemical markers, the assessment of functional genomic markers as a 
component of cardiovascular risk screening offers distinct advantages as well as important 
limitations. For example, the fact that a certain genetic risk profile is static infers the ability to 
assess individual susceptibility long before disease onset is clinically overt. However, an 
associated disadvantage is that the assessment of functional genomic markers does not 
provide sufficient information on whether subclinical vascular disease has progressed over 
time. In this context, certain biomarkers may reflect dysfunction in metabolic pathways early 
on in the disease process, while others provide greater insight into aberrant biological 
activity as clinical risk progresses. Despite the fact that many genetic risk markers are 
strongly associated with the onset and progression of cardiovascular disease, effect sizes 
are often small, with the inclusion of such biomarkers as a component of existing models 
failing to significantly improve their predictive capabilities and diagnostic accuracy. It is 
therefore imperative to establish whether the assessment of functional genomic variants in 
relation to context-dependent determinants of clinical expression adds value to existing 
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clinical risk assessment in order to determine whether genetic testing truly adds independent 
value to patient care (Humphries et al. 2004).  
 
A number of variants in genes such as APOE have been identified as putative susceptibility 
markers for cardiovascular disease, adverse ischemic events and cardiac mortality. In 
particular, a number of case-control and retrospective studies performed since 2007 have 
provided convincing evidence supporting an association between the 9p21 locus and 
increased risk for coronary artery disease due its primary association with an “atherosclerotic 
phenotype”. The association between the 9p21 locus and increased cardiovascular disease 
is independent of other metabolic risk traits including obesity, hypertension and 
dyslipidaemia, with its assessment shown to improve clinical risk prediction in the context of 
coronary artery disease (Holdt and Teupser 2012; Chan et al. 2013). In a genome-wide 
analysis, Surakka et al. (2015) demonstrated that polymorphic variants in genes such as 
APOE known to be implicated in impaired lipid homeostasis explain a sufficient extent of 
inter-individual variance in quantitative metabolic phenotypes associated with cardiovascular 
disease. The assessment of candidate low-frequency variants in genes such as CD300LG 
and TM6SF2 also explained a sufficient additional degree of variance in lipid-related traits. 
The authors concluded that the imputation of uncommon risk variants could offer a more 
cost-effective approach to resequencing using genomic applications including whole exome 
sequencing (WES). Next-generation sequencing has been proposed as a means of 
validating the added benefits of existing genetic risk markers identified in previous genome- 
studies, as well as allowing for the identification of novel causative mutations of large clinical 
effect. 
 
1.9.1. The role of APOE genotyping in the assessment of cumulative risk for 
cardiovascular disease and dementia  
It has been estimated that up to 50% of inter-individual variation in serum lipid profiles is 
inherited. In this context, polymorphic variation in the APOE gene is considered an important 
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determinant of altered cholesterol levels associated with increased risk for premature 
cardiovascular disease (Pablos-Mendez et al. 1997). Three different APOE alleles (ε-2/e-3/ε-
4) encode the three corresponding protein isoforms which differ in their binding affinity for 
cholesterol (E4>E3>E2) (Johnson et al. 2014). In accordance with the physiological effects 
of APOE on hepatic lipid metabolism and clearance, the cholesterol-raising ε-4 allele has 
been identified as an important genetic risk factor for metabolic syndrome, ischemic heart 
disease, stroke and Alzheimer’s disease (AD) (Song et al. 2004; Sima et al. 2007; Verghese 
et al. 2011). APOE ε-4 is considered a major genetic risk factor for dementia as well as a 
determinant of inter-patient heterogeneity in clinical presentation, prognosis and therapeutic 
outcomes in AD due to its pleiotropic effects on disease risk, including an association with 
impaired lipid homeostasis and dyslipidaemia (Figure 2). These observations are in 
accordance with existing evidence which suggests that CVD and AD share a common 
pathogenic basis. As illustrated in Figure 3, a number of mechanisms, including chronic 
inflammation and impaired lipid homeostasis, are shared by both AD and CVD. 
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Figure 2. Relationship between APOE ε-4 and pathogenic mechanisms implicated in 
Alzheimer’s disease (AD). 
 
 
 
Figure 3. Common pathogenic mechanisms shared by Alzheimer’s disease (AD) and 
cardiovascular disease (CVD). 
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Dyslipidaemia is considered an important modifiable risk factor for a number of age-related 
multifactorial conditions including CVD and AD. It has been suggested that APOE genotype 
modifies the association between dyslipidaemia and AD risk (Dufouil et al. 2005). APOE ε-4 
is also an important determinant of clinical heterogeneity in patients with dementia, being 
associated with a primarily amnestic subtype and conversion from mild cognitive impairment 
to AD. It is interesting to note that although the APOE ε-4 allele accelerates disease 
progression in AD, patients who present atypically or at an earlier age seldom carry the risk-
associated allele (Khachaturian et al. 2004; Lam et al. 2013). In patients with AD, APOE ε-4 
allele carriage is strongly correlated with amyloid beta deposition in the leptomeningeal 
arteries resulting in cerebral amyloid arteriopathy (CAA). This common (80%–90%) 
neuropathological characteristic of AD is closely related to structural white matter 
abnormalities, arising secondary to endothelial dysfunction, basement membrane thickening, 
lobar haemorrhages, and vessel stenosis (McCarron and Nicoll 2000). The presence of CAA 
in APOE ε-4 allele carriers may play a synergistic role in disease progression (Love 2004). 
Conflicting evidence however suggests that, while APOE genotype is associated with the 
development of CAA, it is primarily a determinant of cerebral localization, which contributes 
towards focal pathology (Hirono et al. 2000; Kljajevic et al. 2014). Clinical heterogeneity in 
AD is partly a reflection of localized cortical abnormalities, including atrophy and 
hypoperfusion. Executive dysfunction and visuospatial symptoms are associated with 
synucleinopathy and microvascular pathology, focal temporal atrophy with an amnestic 
picture, and parietal pathology with disordered visuospatial processing. Given the reciprocal 
influence of APOE genotype and CAA on parenchymal as opposed to vascular Aβ 
aggregation, further investigation of whether the combined presence of these factors 
influences clinical and therapeutic heterogeneity in AD is also warranted (Liu et al. 2013). 
 
The assessment of APOE genotype could also prove useful in identifying a subgroup of 
patients at increased risk for adverse cardiac events (Peña et al. 2001).  In this context, the 
APOE ε-4 allele has been associated with the development of hypertension, coronary artery 
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disease and ischemic vascular complications in patients at increased cardio-metabolic risk 
(Dzimiri et al. 1999). Khan et al. (2013) also demonstrated a dose-responsive positive 
correlation between the APOE ε-4 genotype and increased low-density lipoprotein (LDL) 
cholesterol levels as well as carotid intima media thickness. The authors however concluded 
that the relationship between the ε-2 allele and ischemic stroke required further investigation. 
In a recent study of six candidate variants implicated in increased cardio-metabolic risk, only 
the APOE ε-4  allele was independently associated with dyslipidaemia, with homozygotes 
exhibiting a more than three-fold increased risk for this quantitative trait compared to non-
carriers (Smolková et al. 2015). The aforementioned findings support the role of APOE 
genotype as a determinant of inter-individual variation in lipids profile and dyslipidaemia risk.  
 
Differentiating between hypercholesterolaemic patients with monogenic dyslipidaemias 
including FH and those carrying the modifier APOE ε-4 allele is important, as treatment 
strategies would differ. A relatively high incidence of mild cognitive impairment has recently 
been reported in FH patients, possibly due to early exposure to elevated cholesterol or low-
density lipoprotein dysfunction (Zambón et al. 2010). The importance of the availability of a 
DNA test for diagnosis of FH as a high-risk cardiovascular subtype (Kotze et al. 2003) is 
emphasized by the clinical variability of this condition, which complicates clinical diagnosis 
(Kotze et al. 1993, 1994). Patients with FH require long-term treatment with lipid-lowering 
medications to reduce their risk of ischemic vascular disease. In contrast, APOE ε-4 carriers 
are less responsive to statin therapy (Baptista et al. 2011). Future investigation is required to 
elucidate the effect of statin therapy in ε-4 allele carriers with AD who are 
normocholesterolemic (Caballero and Nahata 2004). The beneficial role of statins in lowering 
dementia risk appears to be independent of APOE genotype, whereas the association 
between hyperlipidemia and increased dementia prevalence is only evident in patients 
without AD and in ε-4 allele non-carriers. Clinicians should therefore be aware of the genetic 
tests available which could assist in differentiating between FH and other forms of 
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dyslipidaemia where APOE polymorphisms could play a contributory role in disease 
pathogenesis (Table 3).  
Table 3. Comparison between high-penetrance diagnostic testing for familial 
hypercholesterolemia and a combined approach to cardiovascular risk screening and 
management based on the assessment of clinically actionable low- to moderate penetrance 
variants implicated in vascular disease including those associated with dyslipidaemia.  
Test Indications for testing Clinical application 
Familial 
hypercholesterolemia test 
(LDLR gene mutations) 
Increased pre-treatment total 
and low-density lipoprotein 
cholesterol levels 
 
Family history of early-onset 
cardiovascular disease 
 
Clinical signs of familial 
hypercholesterolemia: tendon 
xanthomas, xanthelasma, 
corneal arci etc. 
Used to confirm a suspected 
diagnosis of familial 
hypercholesterolemia  
Chronic disease risk 
screening utilizing a CVD 
multi-gene risk assay 
Normal or abnormal lipid levels 
which can be accompanied by 
impaired glucose tolerance or 
other biochemical 
abnormalities (increased 
homocysteine levels, elevated 
C-reactive protein, etc.) 
 
Increased metabolic risk 
including obesity, hypertension 
and dysglycaemia  
Used to facilitate disease 
prevention through cumulative 
risk reduction for cardiovascular 
disease and associated 
comorbidities guided partly from 
a genetic background  
Familial 
hypercholesterolemia test 
and CVD test 
Combination of the 
abovementioned indications 
Used to characterize treatable 
dyslipidaemia subtypes and 
improve case finding of familial 
hypercholesterolemia in patients 
for whom dyslipidaemia cannot 
be accounted for by clinically 
actionable variants incorporated 
into the multi-gene CVD risk 
assay 
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APOE ε-4 carriers appear to be more vulnerable to the deleterious effects of excessive 
alcohol consumption, cigarette smoking, a sedentary lifestyle, and high dietary intake of 
saturated fat, suggesting interventions targeting these risks may be beneficial in decreasing 
risk aimed at AD prevention (Kivipelto et al. 2008; Valenti et al. 2014). Lowering of 
cumulative risk aimed at AD prevention is very important in APOE ε-4 allele carriers, as the 
benefits associated with many lifestyle-orientated interventions, including regular physical 
exercise and supplementation with omega-3 fatty acids, may be less pronounced or absent 
in AD patients carrying the APOE ε-4 allele (Table 4). Early detection of a genetic 
predisposition for AD is therefore considered an important added benefit of APOE 
genotyping when applied in the context of CVD risk. The clinical application of APOE 
genotyping as part of a multidisciplinary approach to chronic disease risk screening could 
assist clinicians in the implementation of tailored therapeutic interventions in dyslipidaemic 
patients. Given the relatively high frequency of the ε-4 allele in the general population 
globally (30-40%), APOE genotyping could have significant implications for population-based 
risk screening to inform public healthcare policies (Eisenberg et al. 2010).  
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Table 4. Summary of findings from studies which investigated whether APOE genotype 
affects the benefits of lifestyle-based interventions in relation to Alzheimer’s disease risk. 
Study design Lifestyle intervention Clinical interpretation References  
Prospective cohort 
study 
Dietary antioxidant 
intake 
Higher dietary 
antioxidant intake 
decreases risk of 
Alzheimer’s disease 
irrespective of APOE 
genotype 
 
Engelhart et al. 2002 
Prospective study Physical activity Physical activity 
attenuates the effects 
of genetic risk on 
episodic memory in 
individuals free of 
dementia at baseline 
Ferencz et al. 2014 
Prospective study Fish high in omega 3 
fatty acids more than 
two times a week 
Regular consumption 
of foods rich in omega 
3 fatty acids reduces 
Alzheimer’s disease 
risk in APOE ε-4 non-
carriers 
 
Huang et al. 2005 
Prospective study Dietary antioxidant 
intake (vitamin E) 
Adequate dietary 
intake of vitamin E may 
reduce Alzheimer’s 
disease risk in APOE ε-
4 non-carriers without 
dementia at baseline 
 
Morris et al. 2002 
Prospective study Physical activity Physical activity 
normalizes serum lipid 
profiles and related 
metabolic 
abnormalities in APOE 
e-4 allele carriers as 
well as mitigating the 
deleterious effects of 
advancing age on 
multiple biochemical 
disturbances 
associated with 
dementia risk 
Okonkwo et al. 2014 
Randomized control 
trial 
Omega 3 fatty acid 
supplementation 
No effect on clinical 
outcomes in patients 
with mild to moderate 
Alzheimer’s disease 
 
Quinn et al. 2010 
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Up to 80% of interpatient variation in the therapeutic response to medications commonly 
used to treat AD may be explained by genotype (Cacabelos 2008). Multiple studies have 
demonstrated that AD patients who carry the APOE ε-4 allele show a differential response to 
conventional pharmacotherapy. APOE genotype is known to modulate the therapeutic 
effects of acetylcholine esterase inhibitors (AChEI) in patients with AD (Bizzarro et al. 2005; 
Hanson et al. 2015). In this context, findings from several studies suggest that ε-4 allele 
carriers respond more favourably to donepezil (Choi et al. 2008) and rivastigmine (Han et al. 
2012). Evidence concerning the role of APOE genotype as a determinant of the efficacy of 
drugs such as galantamine is however inconclusive (Babić et al. 2004; Suh et al. 2006). 
 
APOE is also considered an emerging therapeutic target in the management of vascular 
disease and dementia. For example, novel treatment modalities such as retinoid X receptor 
(RXR) agonists could pose therapeutic benefit in hypercholesterolaemic patients at risk for 
or diagnosed with AD by modulating APOE lipidation and secretion (Boehm-Cagan and 
Michaelson 2014; Koldamova et al. 2014; Zhao et al. 2014). The observation that RXR-
receptor activation induces APOE up-regulation supports the notion that aberrant retinoid 
metabolism is reciprocally related to impaired cholesterol homeostasis implicated in the 
pathogenesis of AD (Akram et al. 2010). The putative role of APOE in amyloid-beta (Aβ) 
metabolism also infers that retinoids could reduce intra-cerebral peptide deposition and 
neuritic plaque formation (Cao et al. 2007). Retinoids are also known to exert beneficial anti-
inflammatory effects in patients with or at risk for AD by reducing glial production of certain 
cytokines and chemokines (Sodhi and Singh 2014). Findings from phase III RCTs also show 
that treatment with the targeted antibody bapineuzumab prevents amyloid beta deposition 
and decreases levels of phosphorylated tau protein in APOE ε-4 allele carriers but not non-
carriers. These findings suggest that isoform-dependent APOE variation influences the 
efficacy of tailored pharmacotherapy in patients with AD. Side-effects related to 
bapineuzumab, including vasogenic cerebral oedema and micro-haemorrhages, occur more 
frequently in APOE ε-4 carriers. Collectively, these observations support the use of APOE 
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genotyping to guide the selection of appropriate existing and emerging therapeutic 
modalities in patients affected by AD. 
 
2.10. Rationale and aims of study  
There is increasing appreciation for the limitations inherent to single-gene testing in the 
context of genomics-based risk assessment. This is due to the context-dependent nature of 
clinical expression evident for most common low-moderate penetrance susceptibility 
variants. This has led to the development and clinical application of multi-gene panels used 
to guide risk reduction intervention of chronic multifactorial NCDs. The use of multi-gene risk 
assays in conjunction with relevant clinical and biochemical assessments could assist 
clinicians in the identification of treatable NCD subtypes, with the goal of stratifying patients 
into meaningful prognostic subgroups. The ultimate goal is to help inform clinical decision 
making and facilitate the timely implementation of tailored lifestyle-based intervention 
strategies. In order to promote the successful implementation of personalized genomic 
testing in general medical practice, there is however a pressing need to develop 
standardized referral guidelines or pre-screen algorithms for participation in NCD screening 
programs. These criteria could serve to stratify patients based on individual perceived 
benefit, in addition to limiting unnecessary initial referral in cases where it is not indicated. 
The amount of information which can be derived from the assessment of cardiovascular risk 
markers is dependent on where they fit in along the spectrum of pathological processes 
underlying disease progression from a subclinical to overt symptomatic stage. The genotypic 
approach to the assessment of the APOE polymorphism offers several advantages 
compared to phenotypic screening, as noted by Eichner et al. (2002). Despite the well-
established associations between the APOE polymorphism and genetic risk for both CVD 
and AD, there is a pressing need to develop well-defined eligibility criteria used to identify a 
target population set to derive optimal benefit from APOE genotyping. The APOE 
polymorphism (ε-2/ε-3/ε-4) which provides a genetic link between CVD and AD was 
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identified as an important clinical endpoint in cardio-metabolic risk management. Realization 
that the gene effect may be exacerbated by lifestyle risk factors such as smoking and 
alcohol consumption, while the risk of disease development or progression could be reduced 
by regular exercise and maintaining a healthy body weight, supports the inclusion of APOE 
genotyping in chronic disease screening programs. However, the lack of a well-defined 
target population set to derive the greatest benefit from APOE genotyping, as well as clear 
treatment paths based on early detection of a subgroup of dyslipidaemics at increased risk 
of AD, have limited the widespread use of this biomarker in clinical practice. 
 
In this context, the aim of the study was to determine whether the clinical application of a 
study questionnaire could prove useful in assisting clinicians to identify patients eligible for 
APOE genotyping, as well as how results gathered from such testing could be used to 
optimize patient care. Insight gathered as a result of this study may provide the rationale for 
development of a novel pre-screen algorithm, which may lead to conditional approval by 
local medical aid schemes for reimbursement of chronic disease screening including APOE 
genotyping. Implementation of the PSGT approach to APOE genotyping could assist 
clinicians in optimizing cardiovascular risk management in a treatable subgroup of 
dyslipidaemic patients at increased risk of CVD and AD to facilitate cumulative risk reduction 
and improve clinical and therapeutic outcomes. 
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ABSTRACT 
Introduction: The cholesterol-raising properties of the apolipoprotein E (APOE) epsilon-4 (ε-
4) allele has been validated in the South African population. Mounting evidence supports the 
added value of APOE genotyping for the evaluation of cardiovascular risk in dyslipidaemic 
patients beyond its established role in the diagnosis of late-onset Alzheimer’s disease (AD). 
Aim: The aim of this study was to determine the potential benefits of combining AD family 
history with questionnaire-based lifestyle assessment to facilitate the clinical interpretation of 
APOE genotyping results. 
Methods: A total of 580 unrelated South African individuals prospectively enrolled in a 
chronic disease screening program incorporating a genetic component (2010-2015) was 
selected for inclusion in this study based on the presence (75) or absence (505) of AD family 
history. Biochemical assessment of their lipid profiles was performed according to standard 
laboratory protocols. All study participants were genotyped for the APOE ε-2/ε-3/ε-4 alleles 
using allele-specific real-time polymerase chain reaction technology. 
Results: In patients without a family history of AD, APOE genotype modified the relationship 
between alcohol intake and body mass index (p=0.026), with a significant positive correlation 
noted between these parameters being limited to ε-4 allele carriers. APOE genotype also 
modified the association between alcohol intake and total serum cholesterol in patients with 
a positive family history of AD (p=0.026). 
Conclusions: We demonstrated the benefits of a questionnaire-based approach for 
assessment of lifestyle risk factors to facilitate clinical interpretation of APOE genotyping 
results for targeted intervention in a genetic subgroup of dyslipidaemic patients at increased 
risk for AD. 
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INTRODUCTION 
Alzheimer’s disease (AD) and cardiovascular disease (CVD) share common risk factors and 
overlapping pathogenic mechanisms (Cechetto et al. 2008; Kalaria 2010; O’Brien and 
Markus 2014). Recognition that the apolipoprotein E (APOE) gene provides a genetic link 
between vascular disease and dementia creates interest in the value of genetic testing for 
early intervention aimed at decreasing cumulative cardio-metabolic risk to prevent the 
development of late-onset AD with advancing age (Kivipelto and Solomon 2008; Kotze and 
van Rensburg 2012). The addition of a pre-clinical stage to the diagnostic criteria for late-
onset AD (Sperling et al. 2011) offers a critical window of opportunity for the management of 
vascular risk factors at the interface between genes and the environment (Imtiaz et al. 2014). 
Lifestyle-based preventive measures aimed at delaying disease onset by at least one year 
could result in 9.2 million people being spared this devastating diagnosis by the year 2050 
(Brookmeyer et al. 2007). The lack of a well-defined target population set to derive the 
greatest benefit from APOE genotyping used to optimize vascular risk management in a 
subgroup of dyslipidaemic patients at increased risk for AD however constitutes an important 
factor limiting the clinical application of genetic testing in general medical practice. 
The APOE gene has emerged as a useful biomarker which could improve the performance 
of existing risk stratification tools for targeted therapeutic intervention in a high-risk genetic 
patient subgroup (Gauthier et al. 2012; Valenti et al. 2014). APOE offers an aetiological 
bridge between vascular risk factors and cognitive decline, owing to its multifunctional role in 
cholesterol transport and metabolism, amyloid-beta (Aβ) processing, oxidative stress and 
chronic inflammation (Weisgraber 1994). The APOE gene is highly polymorphic, with three 
apolipoprotein isoforms corresponding to the ε-2 (rs7412), ε-3 and ε-4 (rs429358) alleles 
which differ in their binding affinity to the low-density lipoprotein receptor (LDLR) 
(E4>E3>E2). APOE is the primary ligand of the LDLR underlying familial 
hypercholesterolaemia (FH). Isoform-dependent variation in systemic cholesterol 
metabolism and clearance accounts for an extent of inter-patient variation in serum lipid 
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profiles (Johnson et al. 2014). APOE ε-3 considered as neutral is the most common allele 
carried by the general population (de Knijff et al. 1994). The cholesterol-raising effects of 
APOE ε-4 promote atherosclerosis (Davignon 2005; Khan et al. 2013; Zende et al. 2013) 
conferring independent or additive risk for AD (Duron and Hannon 2008). This mechanism is 
mediated by vascular dysfunction attributable to ischemic macrovasculopathy (Kalaria 2000) 
and cerebral amyloid arteriopathy (Love 2004; McCarron and Nicoll 2010), which are in turn 
associated with reduced regional cerebral perfusion known to precede clinically overt 
symptomatic onset in dementia (Bu et al. 2013). 
APOE ε-4 is the most important genetic risk factor for sporadic late-onset AD (Bertram et al. 
2007; Kim 2009; Verghese et al. 2011) and a major determinant of inter-patient 
heterogeneity in clinical presentation, prognosis and therapeutic outcomes (Risacher et al. 
2013; Dixon et al. 2014; Kotze et al 2015a). The APOE ε-4 allele is also associated with 
significant risk for the metabolic syndrome (Sima et al. 2007) and vascular disease 
(McCarron et al. 1999; Song et al. 2004), in addition to mediating the pathogenic relationship 
between these inter-related clinical entities (Teixeira et al. 2014). In keeping with the 
dissociation between APOE ε-2 and hypercholesterolemia (Bazzaz et al. 2010), it has been 
suggested that this allele protects against the onset of ischemic stroke and dementia. 
Recent studies have also proposed that APOE ε-2 is associated with a decreased risk for 
AD due to its modulating effect on cerebral Aβ processing and clearance (Wang et al. 2009; 
Conejero-Goldberg et al. 2014; Serrano-Pozo et al. 2015). The association between APOE 
ε-2 and type III dysbetalipoproteinemia (Blom et al. 2002) as well as the metabolic syndrome 
(van Velden et al. 2011) in South African patients however suggests a deleterious rather 
than beneficial role in the pathogenesis of vascular disease. 
Contradictory findings may be partly explained by the fact that genetic risk conferred by 
these APOE polymorphisms is dependent on a conducive metabolic milieu and influenced 
by environmental as well as epistatic modulators of phenotypic expression (Teixeira et al. 
2014). This observation explains the limited individual utility of APOE ε-2/ε-3/ε-4 as 
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diagnostic and predictive markers in the assessment of vascular risk (Villeneuve et al. 2014). 
The limitations of a genomics-only approach to cardiovascular risk screening can however 
be overcome by including APOE genotyping as part of a multidisciplinary framework 
incorporating diverse patient data gleamed from a variety of sources (Kotze et al. 2015b; 
Lückhoff et al. 2015). The assessment of modifiable dietary habits in this context is 
supported by the well-evidenced association between high saturated as well as trans-fat 
intake and increased risk for AD (Kalmijn et al. 1997; Puglielli et al. 2001; Morris et al. 2003; 
Morris and Tangney 2014). In addition to a direct correlation with increased cerebral Aβ 
burden, a high-fat diet is associated with the metabolic syndrome as an important risk factor 
for cognitive impairment and dementia (Elias et al. 2003; Nguyen et al. 2014). Lifestyle 
habits such as smoking and alcohol intake are also known to exert a dose-dependent effect 
on risk for CVD and AD (Luchsinger et al. 2004; Harwood et al. 2010). In this context, 
findings from a recent South African cross-over alcohol intervention study (Kotze et al. 2014) 
support the role of APOE genotype as a modifier of the association between red wine 
consumption and inter-individual variation in the serum lipid profile.  
The association between APOE ε-4 and increased serum cholesterol levels in patients 
without FH has previously been validated in the South African population by Kotze et al. 
(1993). Despite its potential role in the differential diagnosis of FH, concerns over the added 
value of APOE genotyping in improving clinical outcomes in dyslipidaemic patients were 
initially met with hesitance as to the routine implementation of such testing. This is of 
particular clinical importance given that FH remains vastly underdiagnosed and untreated in 
general medical practice, despite the 5-10 times increased prevalence of this severe form of 
monogenic dyslipidaemia in certain South African population groups (Kotze et al. 1993). In 
South African patients with FH, APOE ε-2 allele carriage is associated with 
hypertriglyceridemia uncharacteristic of the disease state, with second-hit pathologies such 
as obesity and hypothyroidism known to contribute towards the genetic disorder III 
dysbetalipoproteinemia (Blom et al. 2002).  
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The development of a central database resource for translational research linked to a 
genomics-based chronic disease screening program incorporating APOE genotyping 
provided an ideal platform to facilitate the development of referral guidelines for such testing 
in the South African healthcare setting (Kotze et al. 2015b). This database facilitated recent 
local research aimed at determining whether the assessment of non-genetic information 
could assist in identifying patients set to derive optimal benefit from APOE genotyping 
performed in this context. Using this resource, Lückhoff et al. (2015) indeed demonstrated 
that the genotype distribution for APOE ε-2/ε-4 differs between South African individuals with 
and without a family history of AD. In this particular study, the clinical expression of a 
hypercholesterolaemic phenotype in ε-4 allele carriers, as well as its mitigation by regular 
physical activity, was shown to be dependent on the interaction between APOE genotype 
and a family history of AD. The known association between APOE ε-2 and increased 
triglyceride levels was also demonstrated in study participants without a family history of AD. 
In addition, the relationship between the dietary fat score, body mass index (BMI) and serum 
lipid profiles was also dependent on the presence or absence of a self-reported family 
history of AD (Lückhoff et al. 2015). Findings from this study collectively support the role of 
clinical inquiry concerning AD family history alongside the assessment of serum lipid profiles 
as part of a novel pre-screen algorithm used to determine eligibility for APOE genotyping 
performed as an integral component of cardiovascular risk screening and management. The 
added value of APOE genotyping used to optimize vascular risk management in a subgroup 
of dyslipidemic patients is positioned as ancillary to its existing role to improve diagnostic 
reliability for late-onset AD (Sun et al. 2012).  
As an extension of the abovementioned findings, we sought to determine the potential 
benefits of combining family history of AD with non-genetic information for clinical 
interpretation of APOE genotyping results. In particular, we sought to replicate the modifying 
influence of APOE genotype on the association between lifestyle habits and cardio-
metabolic risk traits as demonstrated in previous international studies (Lindsay et al. 2002; 
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Ruitenberg et al. 2002; Mukamal et al. 2003; Harwood et al. 2010) in relation to a self-
reported family history of AD. Insight gathered as a result of this study could provide the 
scientific rationale supporting a multidisciplinary approach to cardiovascular risk screening, 
incorporating APOE genotyping to inform clinical and therapeutic decision making in the 
context of FH case finding, cardio-metabolic risk reduction and AD prevention. 
MATERIALS AND METHODS  
Ethical approval for this cross-sectional genotype-phenotype association study was granted 
by the Health and Research Ethics Committee (HREC) of Stellenbosch University under 
project number N09/08/224. The study was performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki. Written informed consent for 
participation in the research component of a chronic diseases screening program was 
obtained from all study participants. 
Selection of Study Participants 
Data of 580 Caucasian individuals of European Ancestry (404 females, 176 males, mean 
age 46±12 years) were prospectively enrolled in a chronic disease screening program 
incorporating a genomics component. This group included all 537 participants (93%) 
enrolled in our previous study (Lückhoff et al. 2015) as well as an additional 43 eligible 
individuals referred for inclusion in the abovementioned screening program since April 2014. 
Full lipid profiles were determined for a subgroup of 291 patients (50%) enrolled in this study 
following referral by a private practicing clinician or attendance of Wellness Days at the 
workplace or other venues over a five year period (2010-2015) were available in a centrally 
maintained database (accessed at www.gknowmix.org). To exclude ethnicity as a potential 
confounder, and given the small number of non-Caucasian individuals who provided 
informed consent for participation in research linked to a pathology-supported genetic testing 
service, comparative analyses were performed only in the Caucasian study group, who were 
selected based on the presence (75) or absence (505) of a family history of AD.  
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Questionnaire-Based Clinical and Lifestyle Assessment 
Prior to enrolment in the chronic disease screening program, all prospective study 
participants were asked to complete the ethically approved study questionnaire (available at 
www.gknowmix.com) developed in collaboration with a registered dietician and approved by 
the HREC at Stellenbosch University. This questionnaire was used to document socio-
demographic information, clinical data such as body mass index (BMI) and lifestyle factors 
(dietary fat intake, alcohol consumption, smoking). In patients who reported a positive family 
history of AD, the relation to the affected individual was also documented in addition to age 
of onset, as previously described by Lückhoff et al. (2015). Alcohol intake was differentiated 
into abstain, occasionally (1- 2 units/week), moderate (1-13 units/week) and high (14 or 
more units/week). This corresponded to the ordinal categories 0-3 considered for statistical 
analyses. Study participants were also asked how frequently they ate certain foods rich in 
saturated or trans-fats over the course of the preceding three months. This was used to 
derive a dietary saturated and trans-fat score, considered to be moderate when ranging 
between 22 and 26, low between 16-21, very low if <16, and high if ≥27. The practical 
relevance of this dietary fat score as a useful clinical tool in the assessment of lifestyle habits 
in relation to cardio-metabolic risk was previously described in the South African setting by 
Davis et al. (2014). 
APOE Genotyping  
Genomic DNA was extracted from whole blood (QIAamp® DNA Midi-kit) or saliva samples 
(Oragene® reagents). Single nucleotide polymorphisms (SNPs) in the APOE gene (ε-2 
rs7412 and ε-4 rs429358) were genotyped as previously reported (Luckhoff et al. 2015), 
using high throughput real-time polymerase chain reaction (PCR) at the Pathology Research 
Facility, Stellenbosch University. The wild type, heterozygous and homozygous SNP 
genotypes generated for Taqman® SNP Genotyping Assays (Applied Biosystems, 
Werterstadt, Germany) on the Corbett Rotor-Gene™ 6000 series Multiplexing System were 
validated against direct sequencing as the gold standard. 
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Statistical Analysis 
All statistical analyses were performed using the Statistica software package (StatSoft,Inc) 
and R Studio package (freely available at www.r-studio.org). The clinical characteristics of 
participants included in the validation phase of this study (Lückhoff et al. 2015) were 
described and compared between individuals with and without a family history of AD. 
Qualitative characteristics were described using cross-tabulation and frequency tables and 
compared between study groups using the Pearson’s Chi-squared or Fisher’s exact test as 
appropriate. Quantitative phenotypes were described as the means along with standard 
deviations (SD) and compared between study subgroups using a Student’s t-test assuming 
normality of distribution. In cases where quantitative outcomes showed a non-symmetrical 
distribution, such variables were log-transformed for analyses. If the best-fitting log-
transformed model still showed a non-normal distribution, these were described as the 
median with interquartile range (IQR) and compared between study groups using the 
Wilcoxon signed rank test. The linear relationship between the fat score and metabolic risk 
phenotypes was assessed using the Spearman rank correlation coefficient test, for the total 
study groups as well as subgroups defined based on the presence or absence of an AD 
family history. Analysis of covariance (ANCOVA) was used to determine whether APOE 
genotype modified the association between dietary habits and metabolic risk phenotypes. A 
p-value of <0.05 was seen as statistically significant with trend-associations noted where 
applicable. 
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RESULTS 
Clinical characteristics 
The clinical characteristics of the study group are summarized in Table 1 and compared 
between participants with (75) and without (505) a family history of AD. No significant 
differences in age, sex, BMI, serum lipid profiles, alcohol consumption, smoking status or 
dietary fat intake were detected between the two study subgroups (p>0.05). In a separate 
analysis, no significant difference in these parameters were noted for female study 
participants stratified based on the presence or absence of AD family history. There was 
also no difference in the clinical characteristics of patients with and without a family history of 
AD considering the subgroup for whom the full serum lipid profile was assessed (data not 
shown). 
Table 1. Clinical characteristics of study participants summarized and compared based on 
the presence (75) or absence (505) of AD family history. Numerical data is presented as the 
means along with standard deviations (SD) unless otherwise indicated.  
Characteristics Positive AD family 
history 
(n=75) 
Negative AD family history 
(n=505) 
Unadjusted 
P-value 
Age (years) 44.4 (13.0) 46.4 (12.1) 0.19 
Sex (male/female) 18/57 158/347 0.19 
Body mass index (kg/m²) 27.3 (7.1) 27.3 (6.0) 0.97 
Alcohol intake 1.1 (0.8) 
 
1.2 (0.9) 
 
0.30 
Fat score (units) 16.4 (7.8) 16.7 (8.4) 0.79 
Current smoker (yes/no) 5/69 56/437 0.45 
Total cholesterol (mmol/L) 5.1 (1.1) 5.4 (1.1) 0.53 
HDL cholesterol (mmol/L) 1.5 (0.5) 1.4 (0.4) 0.17 
LDL cholesterol (mmol/L) 3.5 (0.8) 3.4 (0.9) 0.72 
Triglycerides (mmol/L) 1.2 (0.8) 1.3 (0.9) 0.50 
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Association between alcohol as well as dietary fat intake and cardio-metabolic risk 
phenotypes in relation to AD family history 
Relationship between smoking and cardio-metabolic risk phenotypes  
In the total Caucasian study group, smoking was associated with higher triglyceride levels 
(p<0.001) and lower HDL cholesterol (p=0.004). No significant association between smoking 
status and BMI (p=0.110), total (p=0.167) or LDL cholesterol levels (p=0.457) was otherwise 
noted. In study participants with a negative family history of AD, the association between 
smoking and triglycerides (p=0.002) as well as HDL cholesterol levels (p=0.022) retained 
significance. No significant relationship between smoking and the selected metabolic risk 
phenotypes of interest were noted for study participants with a positive family history of AD 
(p>0.05). 
Relationship between alcohol consumption and cardio-metabolic risk phenotypes   
In the total Caucasian study group, a trend was observed for alcohol intake to be positively 
associated with total (p=0.070) as well as LDL cholesterol levels (p=0.071). A statistically 
significant inverse association was identified between alcohol intake and HDL cholesterol 
(p=0.009). Alcohol consumption was not otherwise associated with BMI (p=0.603) or 
triglyceride levels (p=0.449) in the total study group. A trend towards a positive association 
between alcohol intake and total cholesterol was also noted for study participants with a 
negative family history of AD (p=0.082). In this subgroup, alcohol intake was not associated 
with BMI (p=0.587), LDL (p=0.121), HDL cholesterol (p=0.201) or triglyceride levels 
(p=0.182). In study participants with a positive family history of AD, a positive association 
was noted between alcohol intake and BMI (p=0.008) as well as triglyceride levels 
(p=0.021). In this subgroup, alcohol intake was not otherwise associated with total 
(p=0.560), LDL (p=0.219) or HDL cholesterol levels (p=0.138). In summary, the association 
between alcohol intake and metabolic risk phenotypes differed based on the presence or 
absence of AD family history. 
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APOE genotype as a modifier of the association between alcohol intake and cardio-
metabolic risk traits  
No significant modifying influence for APOE genotype on the association between lifestyle 
habits and cardio-metabolic risk traits was noted when the total study group was considered. 
A number of differential effects were however observed when participants were stratified 
based on the presence or absence of a self-reported family history of AD. Firstly, APOE 
genotype modified the association between alcohol intake and total cholesterol in study 
participants with a positive family history of AD (p=0.026), with a significant positive 
association between these parameters being limited to ε-4 allele carriers (Figure 1). In this 
subgroup, alcohol intake was also positively associated with total cholesterol levels in 25 
APOE ε-4 allele carriers (Rho=0.35, p=0.085). There was however no significant relationship 
between alcohol intake and total cholesterol levels in 26 APOE ε-4 non-carriers (Rho=-0.29, 
p=0.155). In study participants with a negative history of AD, APOE genotype also modified 
the association between alcohol intake and BMI (p=0.026) with a significant positive 
correlation between these variables again being limited to ε-4 allele carriers (Figure 2). 
There was a significant positive association between alcohol intake and BMI in 163 APOE ε-
4 allele carriers (Rho=0.16, p=0.050). There was however no significant relationship 
between alcohol intake and BMI in 346 APOE ε-4 non-carriers (Rho=-0.05, p=0.413). A 
trend was also noted for APOE genotype to modulate the relationship between alcohol 
intake and HDL cholesterol (p=0.056) with an inverse association being restricted to ε-4 
allele non-carriers. In summary, the interaction between APOE ε-4 and alcohol intake on 
BMI as well as serum lipid profiles was dependent on the presence or absence of a family 
history of AD. 
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Figure 1. Scatterplot diagram illustrating the significant modifying influence of APOE 
genotype on the association between alcohol intake and total serum cholesterol in South 
African patients with a positive family history of AD. 
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Figure 2. Scatterplot diagram illustrating the significant modifying influence of APOE 
genotype on the association between alcohol intake and body mass index (BMI) in patients 
without a family history of Alzheimer’s disease (p=0.026). 
 
DISCUSSION 
In this study, we provide additional evidence substantiating our previous finding that the 
modifying influence of APOE genotype on the association between lifestyle habits and 
selected cardio-metabolic risk phenotypes is influenced by an AD family history. In a recent 
South African cross-over intervention study, a beneficial increase in HDL cholesterol 
associated with moderate alcohol consumption was shown to be less pronounced in APOE 
ε-4 allele carriers (Kotze et al. 2014). In the present questionnaire-based cross-sectional 
study, APOE genotype was identified as a genetic determinant of the relationship between 
alcohol intake and BMI as well as total cholesterol levels, with a deleterious increase in 
these parameters associated with excessive consumption being limited to ε-4 allele carriers. 
The role of AD family history as a determinant of genotypic effects evident from this study 
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was deemed in keeping with our previous observation that its interaction with APOE 
genotype influences the clinical expression of a hypercholesterolaemic phenotype in ε-4 
allele carriers (Lückhoff et al. 2015). These findings therefore collectively support the 
relevance of lifestyle-based assessment positioned alongside clinical inquiry concerning AD 
family history as part of a multidisciplinary approach to chronic disease risk screening 
incorporating APOE genotyping. The added value of genetic testing in this context lies not 
only in prioritizing the need for lifestyle-based intervention aimed at decreasing cumulative 
cardio-metabolic risk in a genetic subgroup of dyslipidaemic patients, but also improving the 
identification as well as guiding the management of South African patients with FH (Kotze 
and van Rensburg 2012). 
Realization that the clinical expression of APOE ε-4 is context-dependent has created 
interest in the value of lifestyle-based interventions to decrease cumulative cardio-metabolic 
risk to prevent the onset and progression of AD in high-risk genetic patient subgroups with 
advancing age. Emerging evidence suggests that simple dietary modifications decrease 
cumulative risk for both CVD and AD while posing minimal potential for added harm 
(Barnard et al. 2014). Although the detrimental effects of environmental exposures on AD 
risk are exacerbated in APOE ε-4 allele carriers (Kivipelto et al. 2008) this patient group 
shows a more favourable response to lifestyle-based as opposed to pharmacological 
interventions compared to non-carriers (Masson et al. 2003; Baptista et al. 2011). The APOE 
ε-4 allele is known to aggravate the deleterious effects of excessive alcohol consumption on 
deranged cholesterol parameters (Ordovas and Mooser 2002). In this study, the 
unfavourable cholesterol-raising effects of excess alcohol intake were restricted to ε-4 allele 
carriers, in keeping with the established role of APOE genotype as a determinant of the 
relationship between alcohol intake and altered serum lipid profiles (Corella et al. 2001). In 
patients with established AD, the synergistic interaction between APOE ε-4 and excessive 
alcohol intake has been associated with a more adverse clinical presentation (Harwood et al. 
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2010). Other studies have however failed to demonstrate the significance of such gene-diet 
interactions on risk for vascular disease including ischemic stroke (Djoussé et al. 2009). 
The modulating effect of APOE ε-4 on the relationship between alcohol intake and HDL 
cholesterol is well-established (Djoussé et al. 2004). APOE genotype has also been shown 
to influence the extent of cardio-protective benefits associated with polyphenol-rich red wine 
consumption in South African patients (Kotze et al. 2014). A questionnaire-based approach 
was used in an attempt to replicate this finding in this study, in which we demonstrated that 
APOE genotype again modified the association between alcohol intake and HDL cholesterol, 
with significantly higher mean levels noted for ε-4 allele carriers compared to non-carriers. 
Multiple prospective studies have demonstrated that long-term moderate alcohol 
consumption is associated with a decreased risk for overall- as well as cardiac mortality 
(Camargo et al. 1997; Gaziano et al. 2000: Fuller 2011; Pai et al. 2012). Adherence to a 
Mediterranean style diet, which places emphasis on the health-promoting effects of 
moderate consumption of certain alcoholic beverages including red wine, has been 
associated with decreased incidence risk for AD as well as cardiovascular mortality 
(Scarmeas et al. 2006; Bonaccio et al. 2015). The cardio-protective benefits of alcohol 
consumption in this context have been attributed to its favourable effects on serum lipid 
profiles (Agarwal 2002). In contrast, hypoalphalipoproteinemia as a component of the 
metabolic syndrome has been shown to confer independent risk for CVD (Reiner et al. 
2011). Collectively, the abovementioned observations suggest that APOE ε-4  carriers are 
not only least likely to derive the same cardio-protective benefits from moderate alcohol 
consumption as non-carriers, but are also more susceptible to the deleterious effects of 
excessive alcohol intake on serum lipid profiles. 
APOE genotype modified the relationship between dietary fat consumption and HDL 
cholesterol in our study cohort, with a detrimental decrease in mean levels with increased 
saturated and trans-fat intake being limited to ε-4 allele carriers with a positive family history 
of AD. It is well-established that the cholesterol-raising effects of APOE ε-4, and 
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homozygosity for this risk-associated allele in particular, are mediated by a high-fat, high-
cholesterol diet (Tikkanen et al. 1990). The differential effects of saturated as opposed to 
moderate unsaturated fat intake on dementia risk is also known to be modified by the APOE 
ε-4 allele. In this context, unsaturated fatty acid intake exerts a protective effect on risk for 
AD, while high saturated fat intake during midlife increases disease risk with advancing age 
(Petot et al. 2003; Laitinen et al. 2006). Excessive dietary intake of saturated and trans-fats 
also increases risk for ischemic vascular disease, which is in turn associated with cognitive 
decline and dementia (Puglielli et al. 2003). Despite the well-evidenced role of APOE 
genotype as a determinant of inter-individual variation in serum lipid profiles, conflicting 
evidence suggests that ε-4 allele carriage does not modify the association between diet and 
body mass on total and LDL cholesterol levels (Petkeviciene et al. 2012). It is appreciated 
that, to date, the majority of studies concerning this topic have failed to consider the role of 
AD family history as a potential confounder in relation to its role as a determinant of 
genotypic effects on disease risk. To what extent the benefits of dietary omega-3 and 
omega-6 fatty acids on dementia risk are attenuated and exacerbated respectively in APOE 
ε-4 carriers however remains incompletely understood (Barberger-Gateau et al. 2007; Morris 
2009). Findings from a recent study by Liang et al. (2013) suggest that, in addition to its 
direct association with dyslipidaemia, APOE genotype is also considered a partial 
determinant of the favourable effects of icosapentaenoic acid (EPA) supplementation on the 
normalization of serum lipid profiles (Liang et al. 2013).  
Findings from our study collectively support the importance of a questionnaire-based 
approach to the assessment of lifestyle risk factors to facilitate the appropriate interpretation 
of information gathered from APOE genotyping performed as an integral component of 
cardiovascular risk screening and management. In this context, genetic testing could prove 
useful in identifying a high-risk subgroup of non-FH dyslipidaemics set to derive the greatest 
benefit from the timely implementation of lifestyle-based intervention strategies aimed at 
decreasing cumulative cardio-metabolic risk to prevent the onset and progression of AD in 
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later life. In particular, emphasis is placed on the role of physical activity in normalizing 
serum lipid profiles and related metabolic abnormalities in APOE ε-4 allele carriers, as well 
as mitigating the deleterious effects of advancing age on multiple biochemical disturbances 
associated with dementia risk (Okonkwo et al. 2014). In this context, the favourable effects 
of exercise in maintaining normal cognition and decreasing the rate of cognitive decline are 
known to be more pronounced in APOE ε-4 carriers (Bernstein et al. 2002; Podelwis et al. 
2005; Obisesan et al. 2012; Farina et al. 2014). 
Several case-control studies (Zamrini et al. 2004; Wong et al. 2013) as well as at least one 
meta-analysis (Rockwood 2006) have reported that statins may prevent the onset and 
clinical progression of dementia. Findings from large-scale prospective follow-up studies 
however fail to support the notion that lipid-lowering pharmacotherapy alters the clinical 
course of AD in patients with an established diagnosis (Feldman et al. 2006). APOE ε-4 
allele carriers are not only least sensitive to the health-promoting benefits of lipid-lowering 
medications (Masson et al. 2003), but statins may in fact exacerbate risk for cerebrovascular 
insults in this genetic patient subgroup (Woo et al. 2013; Romero et al. 2014). In contrast, 
patients with certain monogenic dyslipidaemias including FH (Kotze et al. 1993) require long-
term treatment with lipid-lowering medications to decrease risk for ischemic vascular disease 
(Najam and Ray 2015). APOE genotyping could therefore prove useful in increasing case 
finding for FH in the local healthcare setting while simultaneously preventing statin 
overtreatment in a genetic patient subgroup for whom such treatment is either not indicated 
or could pose additional harm. 
Despite the fact that only 75 participants enrolled in the present study noted a positive family 
history of AD, our findings are in accordance with existing evidence implicating APOE 
polymorphisms in the differential effects of lifestyle habits on metabolic risk phenotypes. An 
important limitation identified for the current study was the fact that a full lipid profile was only 
available for a subset of patients included in the present investigation. However, data 
concerning the parameters for which APOE ε-4 showed a modulating effect were available 
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for the majority of patients enrolled in this study. In addition, restriction of the study group to 
only include Caucasian participants of European Ancestry limited the ability to investigate 
the role of ancestral background as a modifier of functional gene effects in risk allele 
carriers. In this context, future studies are required to further elucidate the putative 
modulating influence of APOE genotype on the association between lifestyle habits and 
cardiovascular risk in underrepresented African population groups (Tishkoff et al. 2009). It is 
further acknowledged that the majority of patients included in this study were female (70%), 
which raises the question to what extent gender modifies the gene effect of APOE 
polymorphisms on AD risk. The selection of a largely female patient group in this study 
reflects the demographics of the total cohort enrolled in a chronic disease screening program 
incorporating a genomics component as discussed above. There was however no difference 
in age, BMI, serum lipid profiles, dietary habits or alcohol consumption noted between 
females with and without a family history of AD. Sex was therefore not considered as an 
important modifier of the gene effect in this study. 
The strengths of this study however lie in the provision of novel local evidence which 
supports the assessment of relevant non-genetic data to facilitate the appropriate clinical 
interpretation of results obtained from APOE genotyping used to optimize the management 
of vascular risk in a high-risk subgroup of dyslipidaemic patients. This notion is based on 
evidence gathered from a practical healthcare setting instead of a controlled research 
environment, which also minimized the potential for pre-selection of the FH phenotype 
(Lückhoff et al. 2015). Biochemical determination of serum lipid profiles in relation to BMI 
relevant to APOE genotyping is positioned as a means of assessing the phenotypic 
expression of the ε-2/ε-3/ε-4 alleles in order to monitor the response to individualized 
treatment aimed at decreasing cumulative risk for CVD and AD with advancing age. The 
lifestyle and dietary questionnaire utilized in this study therefore provides a useful tool for the 
assessment of cumulative environmental risk in relation to genetic disease susceptibility 
conferred by the APOE polymorphism. This approach allowed for the validation of previously 
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described genotype-phenotype associations as well as evaluation of the relationship 
between metabolic risk traits and lifestyle risk factors relevant to vascular disease and 
dementia.  
In summary, we showed that APOE ε-4 genotype modifies the association between alcohol 
and BMI as well as total cholesterol levels, with a tendency for the adverse effects of these 
lifestyle habits to be exacerbated in risk-allele carriers. In addition, our findings suggest that 
the differential expression of these effects is itself influenced by the presence or absence of 
a family history of AD. This notion is in accordance with findings reported in a recent local 
study (Lückhoff et al. 2015) in which we demonstrated that the interaction between APOE 
genotype and AD family history determines the expression of a hypercholesterolaemic 
phenotype in ε-4 allele carriers. Findings from this particular study (Lückhoff et al. 2015) 
support the relevance of clinical inquiry concerning AD family history alongside the 
assessment of serum lipid profiles as part of a novel pre-screen algorithm used to determine 
eligibility for APOE genotyping performed as an integral component of chronic disease risk 
screening to optimize vascular risk management in a high-risk subgroup of dyslipidaemic 
patients. In the present study, we demonstrated the benefits of a questionnaire-based 
approach used for the assessment of lifestyle risk factors to allow for the appropriate clinical 
interpretation of APOE genotyping results within a multidisciplinary framework (Figure 3). 
This approach is positioned as a means to assist clinicians in the development and timely 
implementation of lifestyle-based intervention strategies to decrease cumulative 
environmental risk in a genetic subgroup of dyslipidaemic patients. In this context, APOE 
genotyping could also prove useful in prioritizing the need for statin treatment in addition to 
facilitating the differential diagnosis of FH, which remains underdiagnosed and undertreated 
in the South African healthcare setting (Marais 2004). 
We conclude that, in order to advance the routine clinical implementation of a genomics-
based preventive strategy aimed at combating the health burden imposed by the growing 
global prevalence of AD and dementia, an effective framework is required to support a 
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continuum of research translation aimed at realizing the application of emerging genomic 
technologies to improve quality of life and promote wellness throughout life. 
 
Figure 3. A framework for application of APOE genotyping as an integral part of chronic 
disease risk management focused on prevention of cumulative cardio-metabolic risk 
associated with Alzheimer’s disease in later life. 
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CHAPTER 4 
DISCUSSION AND CONCLUSIONS 
 
 
There is ongoing interest in validating whether genetic testing could add value to risk 
management of patients with cardiovascular disease (CVD). The clinical application of 
genetic testing has long been restricted to a limited diagnostic scope of focusing on high-
penetrance mutation screening for accurate diagnosis of Mendelian disorders such as FH 
(Kotze et al. 1993). In South Africa, the use of a CVD multi-gene assay performed in 
conjunction with biochemistry testing and a questionnaire-based clinical and lifestyle 
assessment (Kotze and Thiart 2003) provided one of the first examples of how genetic 
testing can be applied to identify patient subgroups requiring different treatment strategies 
(Kotze et al. 2015). The development and implementation of a combined research and 
service delivery platform allowed for the characterization of treatable dyslipidaemia subtypes 
using a multidisciplinary approach. The clinical application of this pathology-supported 
genetic testing (PSGT) approach to chronic disease screening provides the opportunity for 
development and refinement of testing algorithms that may help inform clinical and 
therapeutic decision making at an individual level (Kotze et al. 2015). 
Recent evidence supports the added value of genetic testing in the diagnosis of mixed 
hyperlipidaemias associated with the APOE ε-2/ε-3/ε-4 polymorphism, which may result in 
impaired LDL receptor cholesterol binding (Marais et al. 2014). APOE genotyping could 
therefore play an important role in the differential diagnosis of FH and less severe forms of 
dyslipidaemia with the goal of prioritizing the need for tailored pharmacological interventions, 
including statin therapy. The assessment of APOE genotype has however been limited in 
general medical practice due to questions surrounding the clinical utility of APOE genotyping 
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as well as ethical issues inherent to genetic testing of multi-functional variants with reduced 
penetrance. In particular, public anxiety that the use of genetic information for actuarial 
underwriting may negatively impact upon their insurability may contribute to a general 
unease surrounding the relationship between genetics and the insurance industry. To ensure 
the appropriate use of genetic testing in clinical practice, a code of conduct has been 
compiled for the insurance industry in South Africa, which aims to promote the fair, 
equitable, confidential and evidence-based handling of genetic information. Kotze et al. 
(2004) previously reviewed this topic and concluded that genetic testing should not 
negatively impact upon insurability in cases where 1) patients with treatable genetic 
conditions where proof substantiating the efficacy of interventional strategies is sufficient, 2) 
when a family history or clinical symptoms of disease are already present, and 3) when the 
disease-causing mutation is excluded in at-risk relatives of the index patient. The authors 
contrasted different genetic services, emphasizing the distinction between high-penetrance 
mutations used in diagnostic tests for certain monogenic disorders and multi-gene assays for 
complex diseases with a genetic component. The latter is focused on the identification of 
genetic subtypes of treatable multifactorial conditions to guide the development and timely 
implementation of tailored risk reduction and therapeutic strategies aimed at decreasing 
cumulative risk for disease development and progression as well as limiting exposure to 
treatment side-effects and therapeutic failure. 
 
4.1. Ethical considerations 
The issue of cardiovascular genetic testing involving APOE genotyping and actuarial 
underwriting for insurance claims is complicated by the interaction between established legal 
principles and scientific evidence of clinical relevance. The development of increasingly 
complex genomic tools has further complicated the debate on genetic discrimination in the 
context of life insurance. Public fear that genetic data gathered as part of clinical and 
diagnostic work-up can result in discrimination, exclusion, loss of privacy, higher premiums 
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and ultimately negatively impact on their insurability could stifle scientific research and limit 
genomic innovations. This is opposed by the fear that actuarial fairness will not be possible if 
policy holders withhold genetic data from insurance companies, as well as that of adverse 
selection. Currently no consensus has been reached on the criteria and evidence required 
for genetic results to be used in actuarial underwriting (Zick et al. 2005).  However, 
comprehensive case analysis is anticipated to further the development of reimbursement 
policies and strategies that facilitate data collection, inform payers and developers, and 
guard against potential discrimination or exclusion in the genomics era.   
From an ethical viewpoint, a number of aspects should be considered in relation to APOE 
genotyping as well as pre- and post-test handling of patient information. APOE genotyping is 
not recommended as a component of pre-natal testing and is not advised in paediatric 
patients. In symptomatic patients, genetic counselling is recommended in consultation with a 
family member and/or legal guardian/caregiver. It is of critical importance to ascertain the 
clinical profile and age of onset in symptomatic patients, with emphasis on informing family 
members of the risk and mode of inheritance as well as potential indications for further 
testing and evaluation with advancing age. The ethico-legal and moral implications of APOE 
genotyping in asymptomatic high-risk patients remains unclear and the subject of ongoing 
debate regarding the consequences of testing on mental wellbeing and patient care. The 
REVEAL study showed that knowledge of APOE genotype does not result in significant 
short-term psychological distress (Chao et al. 2008). In general, patients are willing to pay 
for this test due to its perceived personal utility of APOE genotyping even in lieu of sufficient 
long-term evidence concerning its clinical utility at the time. Knowledge concerning individual 
genetic risk is however known to be integrated into pre-conceived notions regarding 
personal and familial susceptibility towards late-onset AD. However, the absence of APOE 
polymorphism carriage does not necessarily dissuade patients from the personal believe that 
they are at increased risk for developing AD (Chilibeck et al. 2011). These observations are 
in accordance with the notion that knowledge concerning APOE genotype does not add 
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significant diagnostic or predictive value in the assessment of dementia risk. This 
assumption however fails to take into account the role of APOE not as a diagnostic 
confirmation of a specific disease state, but rather as a tool for the development of tailored 
therapeutic strategies to combat cumulative risk for CVD/AD. 
 
4.2. Clinical validation 
APOE is the primary ligand of the LDLR underlying disease pathogenesis in patients with 
FH. In dyslipidaemic patients with a strong family history of cardiovascular disease which 
cannot be accounted for by the detection of variation in the APOE gene, the possibility of FH 
cannot be ruled out. This diagnosis should be considered in the context of clinical risk factors 
such as obesity and diabetes mellitus as a possible explanation for the presence of a 
deranged serum lipid profile. Kotze et al. (1993) previously described the role of receptor- 
defective (FH1 mutation, D206E) versus receptor-negative (FH2, V408M) mutations as 
causative for this severe monogenic dyslipidaemia known to be 5-10 times more prevalent in 
certain local population groups including Afrikaner patients. In this particular study (Kotze et 
al. 1993), the frequency of the APOE ε-4 allele was 0.17 in non-FH Afrikaner controls, 0.13 
in patients with FH2 and 0.10 in patients with FH1. The authors demonstrated that disease 
severity was related to the type of FH mutation associated with the expression of different a 
phenotypes. Inter-individual variation in phenotypic presentation could not be accounted for 
by the APOE ε-4 allele. Presence or absence of this allele failed to contribute towards an 
additive or synergistic derangement in total serum cholesterol in patients already affected by 
FH as the cause of their medical condition. The aforementioned consideration that high-
penetrance mutation screening for FH should be considered in a subgroup of APOE ε-4 non-
carriers with elevated cholesterol levels is further supported by underrepresentation of this 
allele in South African patients with FH. This effect may be ascribed to selection against the 
APOE ε-4 genotype in FH patients who carry high-penetrance LDLR mutations responsible 
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for their disease. A similar phenotype selection could also partly account for the apparent 
protective effect of the ε-2 allele in the context of ischemic stroke and dementia.  
Sandholzer et al. (1995) have shown that the frequency of the APOE ε-4 allele is two-fold 
higher, and homozyogisty 3-5 fold more common, in the Khoi San population compared to 
Caucasians in South Africa. A number of subsequent studies have confirmed that the APOE 
ε-4 allele is overrepresented in African population groups, which infers an associated 
increase in dose-dependent risk for vascular disease and dementia in the context of a 
Western lifestyle. For example, Zekraoui et al. (1997) demonstrated the frequency of the 
APOE ε-4 allele is 0.41 in African Pygmies and 0.18 in Sub-Saharan study participants. 
Corbo and Scacchi (1999) similarly noted the frequency of the APOE ε-4 allele as 0.41 in 
African Pygmies and 0.37 in the Khoi San population. Overrepresentation of the APOE ε-4 
allele in African patients is also clear from a study conducted by Atadzhanov et al. (2014), 
who demonstrated a frequency of 0.27 in Zambians. The function of the APOE gene product 
was found to be homogeneous across ethnic groups despite differences in population-based 
genetic makeup (Hallman et al. 1991).  
The APOE ε-2 allele has been associated with decreased LDL cholesterol levels in female 
patients with FH (Ferrières et al. 1994). Despite the dissociation between APOE ε-2 and 
hypercholesterolemia, a positive correlation between this allele and increased triglyceride 
levels has been reported in South African patients of African Ancestry (Masemola et al. 
2007). In patients with FH, APOE ε-2 carriage is also associated with hypertriglyceridemia 
uncharacteristic of this severe dyslipidaemia subtype, in addition to being causative of an 
autosomal dominant form of type III dysbetalipoproteinemia (Blom et al. 2002). In South 
African patients, the APOE ε-2 allele was found to be associated with the metabolic 
syndrome (van Velden et al. 2011). These findings collectively argue against the notion that 
APOE ε-2 exerts a protective effect against the development of cardiovascular disease and 
associated complications. The cholesterol-raising effects of the APOE ε-4 allele, as well as 
the association between APOE ε-2 and increased triglyceride levels, were replicated in this 
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translational study despite the fact that the investigation was not performed in a controlled 
research environment. Our findings therefore provide important evidence substantiating the 
clinical validity of APOE genotyping in the local healthcare setting. Analytical validation of 
APOE genotyping has been performed previously as part of the postgraduate study of LR 
Fisher (personal communication).  
 
4.3. Clinical application of APOE genotyping  
The focus of APOE genotyping is mostly on disease management but it also has great 
potential for health management when combined with routine check-ups of serum lipid 
profiles and body weight in addition to related metabolic derangements. The results of these 
assessments are used together with information on medication use, lifestyle and family 
history to determine whether the genetic variations identified have current or future clinical 
relevance. The purpose of the combined pathology and genetic testing approach is to 1) 
identify treatable disease subtypes caused by a combination of genetic and environmental 
factors, 2) facilitate the prevention or lowering of cumulative risk by structured elimination of 
environmental drivers of the disease process and 3) to formulate a risk reduction plan for 
each patient based on the underlying disease mechanisms identified by using well-
established health guidelines adjusted according to the clinical and genetic profile of the 
patient. This can only be accomplished if environmental exposures known to affect the 
expression of the genes included in the test are taken into account and correlated with the 
clinical picture and biochemical blood parameters. This can in turn be used to monitor the 
response to the intervention plan provided in the report. 
For successful incorporation of APOE genotyping as a routine component of cardiovascular 
risk management, it is essential that both the indications for referral as well as the 
implications for treatment are well-established, as supported by the results of this study. 
Understanding that the APOE ε-2/ε-4  alleles investigated in this study are not causal, but 
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exert their detrimental effects under specific circumstances, holds great potential for lowering 
of cumulative disease risk. A lack of referral guidelines for APOE genotyping used to 
optimize cardiovascular risk management therefore limits the potential for clinical translation 
of genomic research in the context of chronic disease risk screening. The selection of a well-
defined target population set to derive optimal benefit from APOE genotyping was identified 
as an important step towards clinical application in South Africa and elsewhere. Assessment 
of relevant clinical and lifestyle data could assist clinicians in determining eligibility for 
genetic testing in the context of dyslipidaemia to allow for the appropriate interpretation of 
APOE genotyping results. 
In accordance with our goal to develop a novel pre-screen algorithm for cardiovascular 
genetic testing, we demonstrated the clinical relevance of inquiry concerning AD family 
history in determining eligibility for APOE genotyping. This was based on clinical expression 
of a hypercholesterolaemic phenotype in ε-4 allele carriers being dependent on the 
interaction between AD family history and APOE genotype. The observation that AD family 
history constituted a determinant of gene expression supports the notion that patients with a 
family history should be considered at high risk and need to be subjected to more regular 
routine follow-up to monitor lipid levels over time. The finding that the cholesterol-lowering 
benefits of physical activity were limited to patients with a positive family history of AD further 
supports the relevance of this variable in the development and implementation of tailored 
lifestyle-based interventions. In addition, we demonstrated that the modifying influence of 
APOE genotype on the association between alcohol, dietary fat intake, BMI as well as total 
cholesterol levels, were also related to cumulative risk associated with a family history of AD. 
These findings collectively support the role of a questionnaire-based clinical and lifestyle 
assessment to facilitate the appropriate clinical interpretation of APOE genotyping results 
performed as part of a comprehensive multidisciplinary approach to cardiovascular risk 
screening and management. 
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From converging lines of evidence, the value of a questionnaire-based approach was 
demonstrated as a useful tool to validate the relationship between metabolic phenotypes and 
lifestyle risk factors in the South African population. In addition, we demonstrated that the 
relationship between these parameters was in certain circumstances also influenced by the 
presence or absence of a family history of AD. In our study, BMI was positively associated 
with LDL cholesterol and inversely associated with HDL cholesterol levels irrespectively of 
AD family history. The dietary fat score was positively correlated with LDL cholesterol and 
inversely associated with HDL cholesterol levels only in study participants with a positive 
family history of AD. Smoking was further associated with higher triglycerides and lower HDL 
cholesterol levels in the total study group. Alcohol intake was positively associated with BMI 
as well as triglyceride levels only in patients with a positive family history of AD. These 
differential effects on the relationship between cardio-metabolic risk traits and modifiable 
lifestyle habits highlighted the importance of clinical inquiry concerning AD family history not 
only as a pre-screen selection step for APOE genotyping, but also as an integral component 
of a multidisciplinary approach to cardiovascular risk management guided partly from a 
genetic background.  
Findings from this research project collectively support the routine clinical application of 
APOE genotyping performed in the context of cardiovascular risk assessment. Importantly, 
APOE genotyping could assist in increasing case finding and diagnosis of monogenic 
dyslipidaemias such as FH, while simultaneously preventing overtreatment with lipid-
lowering pharmacotherapy in cases where it is not indicated or could cause adverse drug 
side effects. In this context, detection of very high LDL-cholesterol levels and/or a strong 
family history of early-onset coronary heart disease that cannot be accounted for by variation 
in the APOE gene should alert clinicians to a possible diagnosis of FH. This condition require 
early initiation of lipid-lowering statins to effectively combat risk for cardiovascular 
complications. Confirmation of APOE ε-4 carrier status in non-FH dyslipidaemic patients 
would allow for the timely implementation of tailored lifestyle-based interventions aimed at 
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decreasing cumulative cardiovascular risk. APOE genotyping is also proposed as a means 
of 1) facilitating clinical follow-up and monitoring for ischemic vascular complications and 
dementia over time, 2) guiding the selection of appropriate existing and emerging 
therapeutic modalities in patients with a confirmed diagnosis of CVD/AD, and 3) informing 
clinical and therapeutic decision making to improve health and well-being. 
The aforementioned clinical applications for APOE genotyping are considered as ancillary to 
its existing role in improving diagnostic reliability for late-onset AD in patients who present 
atypically. In this context, APOE genotyping performed as part of a CVD multi-gene risk 
assay (Kotze and Thiart 2003) could prove useful not only in optimizing cardio-metabolic risk 
screening and intervention, but accurately identifying patients with FH which remains both 
underdiagnosed and undertreated in South Africa (Marais 2004). It however remains 
imperative to perform ongoing validation and comparative effectiveness studies to provide 
further evidence supporting the clinical utility of APOE genotyping. In our study, analytical 
validation of the CVD multi-gene assay as well as replication of the well-established disease-
associated and risk-modulating effects of the APOE polymorphism plays an important role in 
this regard. It is important to establish whether APOE genotyping alters clinical and 
therapeutic decision making to improve patient outcomes and increase quality of life to 
promote overall wellbeing in the South African population. 
Based on the abovementioned observations, a framework is presented which supports the 
implementation of a comprehensive pathology-supported genetic testing strategy 
incorporating APOE genotyping as an integral component of a chronic disease risk 
screening program (Figure 1).  
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Figure 1. Pipeline for the development of a multidisciplinary framework supporting the 
routine implementation of APOE genotyping as a routine component of patient care in the 
context of chronic disease risk screening. 
 
4.4. Conclusions  
In this study, a combined research and service delivery approach was used to develop a 
pre-screen algorithm incorporating AD family history as part of the selection criteria used to 
determine the appropriateness of APOE genotyping. Previously, only clinical indicators 
including dyslipidaemia and other relevant non-genetic lifestyle factors were considered 
suitable selection criteria for application of the CVD multi-gene test. In this context, genetic 
testing is applied to improve cardiovascular risk assessment and optimize cumulative risk 
reduction in a susceptible subgroup of dyslipidemic patients. Evaluation of the wellness 
Stellenbosch University  https://scholar.sun.ac.za
104 
 
genomic profiling performed as an integral part of a chronic disease screening program 
enables selection of the most appropriate therapy for the patient. Treatment failure or drug 
side-effects may however occur in a subset of patients who would then be eligible for 
extended clinical / exome sequencing to identify the causative mutation(s). Application of 
pathology-supported genetic testing may therefore also serve as a pre-screening step to 
determine the appropriateness of extended genetic testing in genetically uncharacterized 
patients. This will be the case when a medical condition exists or the pathology test is 
abnormal in the absence of relevant tested genetic risk factors, meaning that other genetic 
and/or environmental risk factors not covered in the initial test / assessment are responsible 
for the condition. In such situations an extended mutation analysis or pathology testing may 
be recommended as appropriate. A genetic test is usually performed once in a lifetime and 
patients will benefit most when relevant pathology test results are integrated with the genetic 
test results. By looking at the personal and family medical history in the context of the test 
results, it is possible to identify whether any biochemical abnormalities detected could be 
caused by genetics or whether it is most likely environmentally induced and may interact 
with specific genes.  
Regular updating (approximately once a year) of the clinical information (e.g. personal 
medical conditions, cholesterol, weight and diet assessment) online will enable the 
generation of follow-up reports to determine the effectiveness of the proposed intervention 
plan as provided in the report. If no improvements are seen according to pre-set goals, 
adjustment of the treatment plan may be necessary. This is important as an intervention plan 
that may be provided as a patient handout is considered experimental due to the fact that 
the clinical utility has not previously been tested in the context of the unique clinical and 
genetic profile of each individual patient. The incorporation of testing results obtained from 
APOE genotyping into a universally accepted body of knowledge is done according to well-
established principles to optimize cardiovascular risk management with the added goal of 
preventing the onset and progression of AD with advancing age. In accordance with the 
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results obtained in this study, APOE genotyping could assist in identifying a genetic 
subgroup of dyslipidaemic patients set to derive optimal benefit from weight management 
and lifestyle modification. This includes limiting alcohol consumption and decreasing the 
dietary intake of saturated and trans-fats. Regular clinical follow-up and monitoring of serum 
lipid profiles is advised in order to establish the efficacy of lifestyle-based interventions, with 
non-responders considered as potentially eligible to receive statins as part of their treatment 
plan. 
Our findings provided the basis for implementation of a novel pre-screen algorithm for APOE 
genotyping used to assist cardiovascular risk assessment and management. The 
implementation of a research pipeline created an incentive to develop a reimbursement 
policy for the conditional approval of this genetic test by certain local medical aid schemes, 
using an integrated research and service delivery approach. Given the fact that variation in 
the APOE gene affects response to cholesterol-lowering treatment, prevention of statin 
overtreatment is an important consideration in this approach, as illustrated in Figure 2. 
 In addition to a confirmed diagnosis of dyslipidaemia, it is proposed that patients with a 
positive family history of late-onset AD should be considered eligible for APOE genotyping 
following pre-test counselling and obtaining informed consent even if serum lipid profiles are 
normal. In accordance with our finding that AD family history constitutes a determinant of the 
expression of a hypercholesterolaemic phenotype in a genetic subgroup of dyslipidaemic 
patients, APOE polymorphism carriers should be considered at increased cardiovascular risk 
and should be subjected to more regular follow-up to monitor lipid levels. If the patient’s 
clinico-biochemical profile is consistent with a diagnosis of FH, early initiation of statin 
therapy is indicated. Lifestyle-based interventions including weight loss and dietary 
adjustments should be considered first-line therapy in APOE ε-4/ε-2 carriers as well as 
patients at increased cardio-metabolic risk (e.g. obesity) in non-carriers. In accordance with 
our findings, statins should best be avoided in asymptomatic APOE ε-4 carriers, with a 
primary focus on lifestyle-based interventions, including more regular physical activity as well 
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as limiting alcohol consumption and decreasing the intake of dietary saturated and trans-
fats. In APOE ε-2 allele homozygotes, the assessment of “second-hit” pathologies including 
obesity and hypothyroidism which increase the risk of developing type III 
dysbetalipoproteinaemia is warranted. In the presence of hypertriglyceridaemia, these 
patients may also require treatment with lipid-lowering fibrates if a favourable response to 
diet intervention is not achieved. Patients at increased cardiovascular risk for whom severe 
dyslipidaemia could not be accounted for by APOE ε-2/ε-4 carriage, next-generation 
sequencing may be indicated if their clinical profile as well as personal and family medical 
history is not in keeping with FH. 
 
Figure 2. Pre-screen algorithm used to determine eligibility for APOE genotyping performed 
as an integral component of vascular risk management to optimize treatment in 
dyslipidaemic patients. The novel component of this algorithm is the inclusion of assessment 
of AD family history to identify a subgroup of patients set to derive benefit from APOE 
genotyping even in the absence of a deranged lipid profile at baseline/referral. APOE 
genotyping performed in conjunction with a questionnaire-based assessment of clinical and 
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lifestyle risk factors aims to prioritize the need for lifestyle-based as opposed to 
pharmacological interventions to normalize serum lipid profiles. 
In summary, collective evidence gathered from a local healthcare setting supports the 
clinical validity as well as utility of APOE genotyping performed as an integral component of 
cardiovascular risk screening used to optimize cumulative risk reduction across the disease 
spectrum in a high-risk genetic subgroup of dyslipidemic patients. Firstly, the role of clinical 
inquiry concerning AD family as part of a novel pre-screen algorithm is supported to 
determine eligibility for APOE genotyping beyond the assessment of serum lipid profiles. Our 
findings further support the use of a questionnaire-based approach to the assessment of 
lifestyle risk factors to facilitate the accurate clinical interpretation of APOE genotyping 
results within a multidisciplinary framework. The consideration of genetic testing results 
within the context of diverse patient data gleamed from a variety of sources is positioned as 
a response to the limitations inherent to genomics-only risk assessment.  
In conclusion, we demonstrated the appropriateness including the assessment of AD family 
history as a novel component to the pre-screen algorithm used to determine eligibility for 
APOE genotyping. In accordance with international studies, we provided local evidence of 
the interaction between APOE genotype and lifestyle factors known to influence the course 
and progression of both CVD and AD. In particular, the finding that cardiovascular risk may 
be ameliorated by regular physical activity emphasizes the potential of APOE genotyping to 
direct clinical management in high-risk patients to decrease cumulative risk for CVD as well 
as AD. The routine clinical application of APOE genotyping in the local healthcare setting 
has the potential to inform clinical and therapeutic decision making to ultimately improve 
wellness and promote quality of life in dyslipidaemic patients at risk for AD. 
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SUMMARY ON RELEVANT STUDY METHODOLOGY 
The information below describes the methodology used in more detail and the specific  
contributions of the candidate are summarised in relation to each article on pages 54 and 63.  
The study in question involved the retrospective assessment of patient information included 
in a research database linked to a pathology-supported genetic testing (PSGT) service 
conducted at the interface between the laboratory and clinic. This approach has been 
described in the review by Kotze MJ, Luckhoff HK, et al. (2015) as referred to in the thesis.   
This study was not a clinical controlled trial, but performed in an uncontrolled translational 
research/clinical setting. Different private practicing clinicians referred patients for inclusion 
in a chronic disease / wellness screen including a genomics component. We therefore did 
not have control over the process of obtaining a peripheral blood sample for biochemical 
testing performed as part of routine clinical practice. It was however confirmed in personal 
communication with Professors RT Erasmus and SJ van Rensburg that all biochemical 
analyses were performed at accredited laboratories using standardized tests. The pathology 
test results were entered into the database at enrolment of study participants.  
Description of the research model used in this study  
The apolipoprotein E (APOE) ɛ-2/ɛ-3/ɛ-4 polymorphism is the most extensively investigated 
genetic risk factor for late-onset Alzheimer’s disease (AD). The risk-associated APOE ɛ-4 
allele provides a genetic link between cardiovascular disease (CVD) and AD owing to its 
pathogenic associations with numerous metabolic abnormalities including impaired lipid 
homeostasis which formed the basis of this study. A number of factors however limits the 
clinical application of APOE genotyping as a biomarker with probable clinical utility in general 
medical practice. These include the lack of well-defined eligibility criteria used to identify a 
target population of dyslipidaemic patients set to derive optimal benefit from APOE 
genotyping used to inform clinical and therapeutic decision making. Another clinical dilemma 
is represented by concerns regarding the ethical implications of APOE genotyping. Towards 
the goal of overcoming these limitations, a local study was designed utilizing a combined 
research and service delivery approach facilitated by the retrospective assessment of 
comprehensive patient information included in a secure research database. The 
implementation of a learning healthcare system (Figure 1) in this context provided an 
invaluable tool to allow research findings to inform and influence practice guidelines and 
clinical decision making. Results obtained outside a controlled research setting was 
evaluated against existing international studies for implementation during a pilot study. This 
preliminary data served as the basis for the development of a pre-screen selection algorithm 
for APOE genotyping incorporating clinical inquiry concerning AD family history as a novel 
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component used to direct eligibility for APOE genotyping as part of a multi-gene CVD assay. 
This approach served in itself as the basis for development of a reimbursement policy for 
APOE genotyping as discussed by Prof Manie de Klerk (presented at the 10th Applied 
Genetics Workshop, 30 October 2015). The assessment of large-scale prospective patient 
data based on this prescribed algorithm would allow for its continual improvement, based on 
evidence that APOE genotyping does influence patient care, with specific regard to the 
necessity for lipid-lowering statin therapy in ɛ-4 carriers. Risk-benefit and cost-effectiveness 
studies would prove useful in determining the feasibility and clinical utility of APOE 
genotyping in the local clinical domain. The dissemination of these findings through a 
continuum of research translation would allow for large-scale improvements in patient care 
as well as assist in identifying potential issues which could hinder the routine implementation 
of APOE genotyping as a component of chronic disease risk screening and management.  
 
 
 
 
Figure 1. Pipeline for the implementation of a learning healthcare system to allow for the 
conditional approval of APOE genotyping used to direct patient care and inform clinical 
decision making in the South African setting (source: 
http://www.slideshare.net/grouphealth/learning-health-care-systems).  
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Data analysis and statistical methods examples 
The pathology-supported genetic testing (PSGT) approach emphasizes the importance of 
considering genetic testing within the context of diverse phenotypic data gleamed from a 
variety of sources and linked by the common thread of pathological assessment. Prior to 
genetic testing using an analytically validated multi-gene assay, all prospective patients are 
asked to complete an ethically approved Medical History and Lifestyle Questionnaire 
(available at www.gknowmix.com) used to document information on personal and family 
medical history, relevant clinical data and medication use. This information is used to 
determine eligibility for genetic screening with the goal of preventing unnecessary testing or 
initial referral in cases where the health concerns are unlikely to be addressed. Results from 
genetic testing are considered within the context of clinical data and provided as an 
integrated interpretive report to the referring clinician, including suggestions as to 1) how 
lifestyle changes and adjustment to dietary habits could possibly be used to mitigate relevant 
risk factors as guided partly from a genetic background, as well as 2) to what extent existing 
treatment could be altered or dosages changed to decrease risk for treatment-related side-
effects in addition to therapeutic intolerance and/or failure. This approach is aimed at 
increasing treatment compliance and improving quality of life. 
Information obtained from patients who provided written informed consent for research 
participation were filtered through to the back-end of the patient database (accessed at 
www.gknowmix.org), which contains the data suitable for research use. In an attempt to 
maintain anonymity, each patient was assigned an automatically generated reference 
number with patient names and other identifiers removed as appropriate for uploading to the 
research database. After the necessary data fields are selected for a specific study, the 
patient information is extracted and exported to an Excel document for statistical analysis. 
In order to facilitate communication between the researcher and statistician, it is essential 
that a standardized report containing a summary of the relevant patient data as well as 
research aims and objectives is made available. Towards this goal, a semi-automated online 
template was developed for presenting data to a bioinformatician or statistician. This 
template includes the necessary preliminary statistical tests which was performed by the 
candidate in order to describe patient data and communicate this effectively in line with the 
project goals. 
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Input of dataset into 
statistical program and 
testing whether numerical 
data is normally distributed 
1) Input dataset into R Studio 
>read.table(file=”dataset.csv”,header=T,sep=”;”,dec=”.”,colClasses=
c(“numeric”,”factor”))->dat1 
2) Determine whether continuous numerical data is normally 
distributed using the Shapiro-Wilk test (example for age) 
>m1=mean(dat1$AGE,na.rm=T) 
>m1 
>s1=sd(dat1AGE,na.rm=T) 
>s1 
>normvec1=rnorm(150,mean=m1,sd=s1) 
>shapiro.test(normvec1) [p<0.05 – normally distributed] 
3) Describe normally distributed numerical data as the means along 
with standard deviation (SD) and non-normal data as the median 
along with interquartile range (IQR) 
Sex-based comparison of 
clinical and biochemical 
characteristics as well as 
lifestyle and dietary habits 
of study participants 
Create subset for males and females 
>subset(dat1,SEX==0)->df1 
>subset(dat1,SEX==1)->df2 
Calculate the means and standard deviation for each numerical 
variable for both males and females 
Compare numerical data between males and females using a 
Student’s t-test (example for age) 
>df1$AGE->vect1 
>df2$AGE->vect2 
>t.test(vect1,vect2) = provides p-value 
Compare categorical data by creating a contingency table and using 
the Chi-squared test or Fisher’s test if cell counts are equal to or less 
than five 
>contingency1=matrix(c(10,20,30,30,20,10),nrow=3) 
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>chisq.test(contingency1) 
>contingency2=matrix(c(5,10,20,20,10,5),nrow=3) 
>fisher.test(contingency2) 
Comparison of genotype 
distributions and minor 
allele frequency for genetic 
variant(s) of interest 
between patient groups 
Determine genotype distribution by allele count and test for Hardy-
Heinberg equilibrium (HWE) for both groups using an exact test [link: 
HWE calculator] and describe findings in a separate table. Compare 
genotype distribution(s) and minor allele frequencies using either the 
Chi-squared test or logistic regression analysis to comment on to 
what extent the variant of interest confers risk for the condition of 
interest 
Chi-squared test: 
>contingency3=matrix(c(40,50,10,30,50,20),nrow=3) 
>chisq.test(contingency) 
Logistic regression analysis (considering one variant of interest) 
Create a column (PC) with patients and controls coded as 
controls=0 and patients=1, and considering the variant of interest 
e.g. MTHFR 677C>T coded as M677 with CC=0, CT=1 and TT=2: 
>library(MASS) 
>step_with_mult=stepAIC(glm(PC~M677,data=dat1,family=binomial(
link=”logit”))) 
>summary(step_with_mult) 
Describe with odds ratios (OR) and 95% confidence intervals (CI) 
>exp(cbind(OR=coef(step_with_mult),confint(step_with_mult))) 
 
For the two sub-studies, the qualitative characteristics of interest in this study were: sex, 
alcohol intake, physical activity, smoking status and statin use. The quantitative phenotypes 
of relevance to this study were: age, body mass index, the fat score, as well as the 
components of the lipid profile (total, HDL, LDL cholesterol and triglyceride levels). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
